	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S74-PMC2290997	PMC2290997	4/2008	S74-PMC2290997	['STILL to be resolved, HOWEVER, is the QUESTION of WHAT levels of Vitamin D are OPTIMAL for preventing the disease—and WHETHER the statistical ASSOCIATIONS REFLECT DIFFERENT Gene pools RATHER than DIFFERENT levels of 25(Oh)D. (INTERESTINGLY, holick REPORTED in the august 1988 issue of the journal of clinical endocrinology & Metabolism that no previtamin d3formed when Human skin was exposed to sunlight on cloudless days in boston, at 42.2°n, from november through february or in edmonton, at 52°n, from october through march.)']	[('IMPORTANT_CONSIDERATION', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 22), ('EXPLICIT_QUESTION', 38), ('EXPLICIT_QUESTION', 50), ('IMPORTANT_CONSIDERATION', 79), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 118), ('EXPLICIT_QUESTION', 118), ('SUPERFICIAL_RELATIONSHIP', 142), ('SUPERFICIAL_RELATIONSHIP', 155), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 163), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 184), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 196), ('ANOMALY_CURIOUS_FINDING', 226), ('INCOMPLETE_EVIDENCE', 248)]	14	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('SO_0000704', 'gene', 173, 'gene'), ('CHEBI_71657', 'versiconol acetate', 216, '25(OH)D'), ('GO_0008152', 'metabolic process', 325, 'Metabolism'), ('NCBITaxon_9606', 'Homo sapiens', 369, 'human')]
S125-PMC2821652	PMC2821652	2/2010	S125-PMC2821652	['our analytic technique, HOWEVER, is UNIQUE in that it utilizes the pharmacokinetics of Vitamin D Metabolism to PREDICT adherence, and the data are then compared to pill counts.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 24), ('ANOMALY_CURIOUS_FINDING', 36), ('SUPERFICIAL_RELATIONSHIP', 111)]	3	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0008152', 'metabolic process', 97, 'metabolism')]
S128-PMC2873552	PMC2873552	4/2010	S128-PMC2873552	"[""caption (table-wrap): table 2\n\nfunctions and diseases related to both ceu and yri Signaturesceuyri diabetes 1.70e-172.70e-20 Coronary Artery disease 3.78e-173.12e-13 Genetic disorder 1.09e-144.53e-14 Cardiovascular disease 1.34e-144.78e-11 non-Insulin-dependent diabetes mellitus 1.03e-128.66e-15 Endocrine System disorder 1.91e-121.25e-18 hypertension 2.13e-122.83e-11 Neurological disorder 2.49e-123.27e-12 crohn's disease 7.59e-127.25e-09 bipolar affective disease 3.50e-115.24e-09 Metabolic disorder 5.66e-119.83e-16 inflammatory disorder 2.56e-091.08e-08 Digestive System disorder 2.66e-091.31e-07 Skeletal and muscular disorder 1.49e-081.58e-08 progressive motor neuropathy 2.53e-085.59e-12 Autoimmune disease 7.28e-081.09e-12 immunological disorder 2.46e-073.66e-13 rheumatoid arthritis 3.78e-072.54e-07 shape change of Epithelial Cells 8.86e-07 alzheimer's disease 3.60e-062.27e-07 parkinson's disease 7.24e-065.29e-06 shape change of Dermal Cells 9.33e-06 Insulin-dependent diabetes mellitus 3.76e-15 neuropathy 5.38e-12 amyotrophic lateral sclerosis 1.36e-09 arthritis 1.44e-07\n\nVitamin D HYPOTHESIS\nan INTERESTING HYPOTHESIS HAS BEEN PROPOSED by mcgrace [28] claiming that low Prenatal Vitamin D increases the risk of a wide range of diseases such as multiple sclerosis, diabetes, schizophrenia, Prostate cancer, Breast cancer and Colorectal cancer because of its versatile function in normal development.""]"	[('INCOMPLETE_EVIDENCE', 1099), ('ANOMALY_CURIOUS_FINDING', 1113), ('INCOMPLETE_EVIDENCE', 1125), ('INCOMPLETE_EVIDENCE', 1136), ('INCOMPLETE_EVIDENCE', 1145)]	5	[('GO_0036367', 'light adaption', 82, 'signaturesCEUYRI'), ('UBERON_0001621', 'coronary artery', 125, 'Coronary artery'), ('SO_0000704', 'gene', 166, 'Genetic'), ('UBERON_0004535', 'cardiovascular system', 200, 'Cardiovascular'), ('PR_000045358', 'insulin family protein', 244, 'insulin'), ('UBERON_0000949', 'endocrine system', 297, 'Endocrine system'), ('UBERON_0001016', 'nervous system', 370, 'Neurological'), ('GO_0008152', 'metabolic process', 485, 'Metabolic'), ('UBERON_0004854', 'gastrointestinal system mesentery', 560, 'Digestive system'), ('UBERON_0004288', 'skeleton', 603, 'Skeletal'), ('UBERON_0005445', 'segment of pes', 697, 'Autoimmune'), ('CL_0000066', 'epithelial cell', 827, 'epithelial cells'), ('UBERON_0000483', 'epithelium', 827, 'epithelial'), ('CL_0000346', 'hair follicle dermal papilla cell', 943, 'dermal cells'), ('PR_000045358', 'insulin family protein', 965, 'Insulin'), ('CHEBI_28384', 'vitamin K', 1089, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1188, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1197, 'vitamin D'), ('UBERON_0002367', 'prostate gland', 1307, 'prostate'), ('UBERON_0000310', 'breast', 1324, 'breast'), ('UBERON_0012652', 'colorectum', 1342, 'colorectal')]
S117-PMC2874518	PMC2874518	6/2010	S117-PMC2874518	['a RECENT-meta-analysis of seven studies CONCLUDED that combined Vitamin C and e supplementation had no potential benefit in the improvement of maternal and neonatal outcome and increased the risk of Gestational Hypertension in women at risk of pre-eclampsia.26\nit is WELL ESTABLISHED that there are significant INTERACTIONS between Micronutrients and their Metabolism.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 40), ('INCOMPLETE_EVIDENCE', 267), ('PROBABLE_UNDERSTANDING', 267), ('SUPERFICIAL_RELATIONSHIP', 311)]	5	[('CHEBI_27300', 'vitamin D', 64, 'vitamin C'), ('GO_0007549', 'dosage compensation', 199, 'gestational hypertension'), ('CHEBI_33839', 'macromolecule', 332, 'micronutrients'), ('GO_0008152', 'metabolic process', 357, 'metabolism')]
S41-PMC2913107	PMC2913107	8/2010	S41-PMC2913107	['a comment to the authors (20) DETAILED the EVIDENCE that Antiepileptic Drugs are one of the few classes of Drugs that CONSISTENTLY and SIGNIFICANTLY INTERFERE with Vitamin D Metabolism, lowering 25(Oh)D levels.']	[('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 43), ('PROBABLE_UNDERSTANDING', 118), ('IMPORTANT_CONSIDERATION', 135), ('SUPERFICIAL_RELATIONSHIP', 149)]	5	[('CHEBI_35218', 'anthocyanin cation', 57, 'antiepileptic'), ('CHEBI_23888', 'drug', 71, 'drugs'), ('CHEBI_23888', 'drug', 107, 'drugs'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('GO_0008152', 'metabolic process', 174, 'metabolism'), ('CHEBI_71657', 'versiconol acetate', 195, '25(OH)D')]
S126-PMC2963768	PMC2963768	10/2010	S126-PMC2963768	['the most WIDELY-accepted manifestation of SEVERE Vitamin D deficiency in infancy is rickets, the classical childhood Metabolic bone disease ASSOCIATED with Skeletal hypomineralization and deformities, muscle weakness, and growth impairment (1).']	[('PROBABLE_UNDERSTANDING', 9), ('IMPORTANT_CONSIDERATION', 42), ('SUPERFICIAL_RELATIONSHIP', 140)]	3	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0008152', 'metabolic process', 117, 'metabolic'), ('UBERON_0004288', 'skeleton', 156, 'skeletal')]
S102-PMC3032617	PMC3032617	5/2010	S102-PMC3032617	['INTERESTINGLY, ALTHOUGH the average weight gain was normal in the two groups during Pregnancy without any significant statistical difference, this was FOUND lower in the Vitamin C group COMPARED TO controls, and this COULD SUGGEST the POSSIBILITY of a better Fatty Acid Catabolism provided by high dose Vitamin C intake which IS KNOWN to enhance Carnitine synthesis, a fundamental long chain Fatty Acid transporter to the Mitochondrial site for energy production in form of atp, also, Ascorbic Acid is INVOLVED in the biosynthetic pathway of Thyroid hormones which are known regulators of the basal Metabolism.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 15), ('INCOMPLETE_EVIDENCE', 151), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 186), ('INCOMPLETE_EVIDENCE', 217), ('INCOMPLETE_EVIDENCE', 223), ('INCOMPLETE_EVIDENCE', 235), ('INCOMPLETE_EVIDENCE', 326), ('SUPERFICIAL_RELATIONSHIP', 502)]	9	[('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin C'), ('CHEBI_35366', 'fatty acid', 259, 'fatty acid'), ('GO_0009062', 'fatty acid catabolic process', 259, 'fatty acid catabolism'), ('CHEBI_27300', 'vitamin D', 303, 'vitamin C'), ('CHEBI_17126', 'carnitine', 346, 'carnitine'), ('GO_0015915', 'fatty-acyl group transport', 392, 'fatty acid'), ('GO_0005739', 'mitochondrion', 422, 'mitochondrial'), ('CHEBI_22652', 'ascorbic acid', 485, 'ascorbic acid'), ('CHEBI_9437', 'temoporfin', 542, 'thyroid'), ('UBERON_0002046', 'thyroid gland', 542, 'thyroid'), ('GO_0008152', 'metabolic process', 599, 'metabolism')]
S142-PMC3171895	PMC3171895	9/2011	S142-PMC3171895	['smoking HAS BEEN SHOWN to increase oxidative stress and Metabolic turnover of Vitamin C, thus the REQUIREMENT for smokers is increased by 35\u2009mg/day [79].']	[('INCOMPLETE_EVIDENCE', 8), ('IMPORTANT_CONSIDERATION', 98)]	2	[('GO_0008152', 'metabolic process', 56, 'metabolic'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin C')]
S79-PMC3257641	PMC3257641	3/2010	S79-PMC3257641	['Human STUDIES ARE NEEDED AS inter-species variation in Vitamin D REQUIREMENTS and Metabolism MAY occur [55].']	[('FUTURE_WORK', 6), ('PROBABLE_UNDERSTANDING', 25), ('IMPORTANT_CONSIDERATION', 65), ('INCOMPLETE_EVIDENCE', 93)]	4	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Human'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('GO_0008152', 'metabolic process', 82, 'metabolism')]
S197-PMC3277098	PMC3277098	12/2011	S197-PMC3277098	['these CONTRASTING results HIGHLIGHT THE NEED for randomised controlled trials (rct) to provide clearer picture of ROLE of Vitamin D during infancy in Regulation of Allergic disease, including uptake, Metabolism and Immunomodulation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 6), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 36), ('FUTURE_WORK', 40), ('SUPERFICIAL_RELATIONSHIP', 114), ('SUPERFICIAL_RELATIONSHIP', 150)]	6	[('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('GO_0065007', 'biological regulation', 150, 'regulation'), ('GO_0040011', 'locomotion', 164, 'allergic'), ('GO_0008152', 'metabolic process', 200, 'metabolism'), ('GO_0050900', 'leukocyte migration', 215, 'immunomodulation')]
S18-PMC3347028	PMC3347028	3/2012	S18-PMC3347028	['during this foray into the world of Vitamin D and the fetus, we MUST first define WHAT Vitamin D is, WHAT it is not, and review the Metabolic pathways LINKED with Vitamin D.\n\n2.']	[('IMPORTANT_CONSIDERATION', 64), ('EXPLICIT_QUESTION', 82), ('EXPLICIT_QUESTION', 101), ('SUPERFICIAL_RELATIONSHIP', 151)]	4	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0008152', 'metabolic process', 132, 'metabolic'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D')]
S18-PMC3424155	PMC3424155	8/2012	S18-PMC3424155	['moreover, Vitamin D is ASSOCIATED with premature births, obesity and Renal dysfunction in Adulthood, making it more than an ESSENTIAL fat-soluble Vitamin RESPONSIBLE for calcium Metabolism[9],[10].']	[('SUPERFICIAL_RELATIONSHIP', 23), ('IMPORTANT_CONSIDERATION', 124), ('PROBABLE_UNDERSTANDING', 154)]	3	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('UBERON_0002113', 'kidney', 69, 'renal'), ('UBERON_0000113', 'post-juvenile adult stage', 90, 'adulthood'), ('CHEBI_33229', 'vitamin (role)', 146, 'vitamin'), ('GO_0008152', 'metabolic process', 178, 'metabolism')]
S208-PMC3424155	PMC3424155	8/2012	S208-PMC3424155	['the MAJOR AIM of the study was TO INVESTIGATE Glomerular Development and Renal structure at Birth, 10 days and Adulthood in Mice Born to mothers Fed a diet restricted in Vitamin D. ALTHOUGH, we EXAMINED OTHER variables, such as body mass and 24 h Urine, the PRESENT STUDY was NOT DESIGNED TO investigate Renal functional and Metabolic CONSEQUENCES BUT RATHER was DESIGNED TO answer the QUESTION of WHETHER there were structural, Glomerular alterations or transgenerational EFFECTS.']	[('IMPORTANT_CONSIDERATION', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 31), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 181), ('QUESTION_ANSWERED_BY_THIS_WORK', 194), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 203), ('QUESTION_ANSWERED_BY_THIS_WORK', 258), ('INCOMPLETE_EVIDENCE', 276), ('IMPORTANT_CONSIDERATION', 335), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 348), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 352), ('QUESTION_ANSWERED_BY_THIS_WORK', 363), ('EXPLICIT_QUESTION', 386), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 398), ('SUPERFICIAL_RELATIONSHIP', 473)]	15	[('GO_0032835', 'glomerulus development', 46, 'glomerular development'), ('UBERON_0000074', 'renal glomerulus', 46, 'glomerular'), ('UBERON_0002113', 'kidney', 73, 'renal'), ('GO_0007567', 'parturition', 92, 'birth'), ('UBERON_0000113', 'post-juvenile adult stage', 111, 'adulthood'), ('NCBITaxon_10088', 'Mus <genus>', 124, 'mice'), ('GO_0007567', 'parturition', 129, 'born'), ('GO_0007631', 'feeding behavior', 145, 'fed'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D'), ('UBERON_0001088', 'urine', 247, 'urine'), ('UBERON_0002113', 'kidney', 304, 'renal'), ('GO_0008152', 'metabolic process', 325, 'metabolic'), ('UBERON_0000074', 'renal glomerulus', 429, 'glomerular')]
S18-PMC3427192	PMC3427192	4/2012	S18-PMC3427192	['1,25(Oh)2D3, also referred to as Calcitriol, is then transported throughout the body via the Blood to various cells types that Express vdrs, where Gene Expression is induced.24,39BECAUSE the MAJORITY of Vitamin D Metabolism occurs in this skin, several FACTORS ARE THOUGHT TO INFLUENCE Vitamin D skin Metabolism, including age, body fat, the level of skin Melanin, and OTHER variables such as latitude, the amount and degree of sun exposure, and use of sunscreen products with uv protection.40these FACTORS HAVE BEEN PREVIOUSLY ASSOCIATED with Vitamin D deficiency in epidemiologic studies.41-43\n\ncaption (fig): figure 2.']	[('PROBABLE_UNDERSTANDING', 177), ('PROBABLE_UNDERSTANDING', 191), ('SUPERFICIAL_RELATIONSHIP', 253), ('INCOMPLETE_EVIDENCE', 261), ('INCOMPLETE_EVIDENCE', 265), ('SUPERFICIAL_RELATIONSHIP', 276), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 369), ('SUPERFICIAL_RELATIONSHIP', 499), ('INCOMPLETE_EVIDENCE', 507), ('INCOMPLETE_EVIDENCE', 517), ('SUPERFICIAL_RELATIONSHIP', 528)]	11	[('CHEBI_37958', 'dye', 0, '1,'), ('CHEBI_73394', 'Ala-Ser', 2, '25(OH)2D3'), ('CHEBI_17823', 'calcitriol', 33, 'calcitriol'), ('UBERON_0000178', 'blood', 93, 'blood'), ('GO_0010467', 'gene expression', 127, 'express'), ('GO_0010467', 'gene expression', 147, 'gene expression'), ('SO_0000704', 'gene', 147, 'gene'), ('CHEBI_27300', 'vitamin D', 203, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 203, 'vitamin D metabolism'), ('CHEBI_27300', 'vitamin D', 286, 'vitamin D'), ('GO_0008152', 'metabolic process', 301, 'metabolism'), ('CHEBI_25179', 'melanins', 356, 'melanin'), ('CHEBI_27300', 'vitamin D', 544, 'vitamin D')]
S65-PMC3427192	PMC3427192	4/2012	S65-PMC3427192	['Haplotype analysis of the vdr polymorphisms SHOWED a significant ASSOCIATION with asthmavollmert90200432munich, germany/ germansnps in the vdr and Integrin Β7None of the Snps were ASSOCIATED with asthmawjst912005951munich, germany/ germany and sweden13 Snps in the vdrin unaffected siblings, Allele in the 5′ region was undertransmitted while two other Alleles in the 3′ terminal region were overtransmittedwjst922006947munich, germany/ germany and swedenserum levels of Vitamin D and genotyping of dna Single Base variantsat least one positive Snp with a transmission disequilibrium of for asthma or total Ige and Vitamin D was FOUND in several Genes\nONLY a HANDFUL OF STUDIES have evaluated the LINK between asthma and polymorphisms in other Genes INVOLVED in Vitamin d synthesis, bioavailability and Metabolism.']	[('INCOMPLETE_EVIDENCE', 44), ('SUPERFICIAL_RELATIONSHIP', 65), ('SUPERFICIAL_RELATIONSHIP', 180), ('INCOMPLETE_EVIDENCE', 629), ('INCOMPLETE_EVIDENCE', 652), ('INCOMPLETE_EVIDENCE', 659), ('SUPERFICIAL_RELATIONSHIP', 697), ('SUPERFICIAL_RELATIONSHIP', 750)]	8	[('SO_0001024', 'haplotype', 0, 'Haplotype'), ('PR_000009070', 'integrator complex subunit 3', 147, 'integrin β7None'), ('SO_0000694', 'SNP', 170, 'SNPs'), ('SO_0000694', 'SNP', 253, 'SNPs'), ('SO_0001023', 'allele', 292, 'allele'), ('SO_0001023', 'allele', 353, 'alleles'), ('CHEBI_27300', 'vitamin D', 471, 'vitamin D'), ('SO_0000984', 'single', 503, 'single base'), ('SO_0000694', 'SNP', 545, 'SNP'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 607, 'IgE'), ('CHEBI_27300', 'vitamin D', 615, 'vitamin D'), ('SO_0000704', 'gene', 646, 'genes'), ('SO_0000704', 'gene', 744, 'genes'), ('CHEBI_33229', 'vitamin (role)', 762, 'vitamin'), ('GO_0008152', 'metabolic process', 803, 'metabolism')]
S66-PMC3427192	PMC3427192	4/2012	S66-PMC3427192	['in ONE STUDY, modest ASSOCIATIONS were NOTED between several Genes in the Vitamin D pathway and asthma and allergic sensitization in populations enriched for subjects with current asthma.86a separate study of asthmatics also FOUND Haplotype ASSOCIATIONS for Cyp24A1 , the primary enzyme ASSOCIATED with Calcidiol Metabolism, where a 5-point Haplotype was ASSOCIATED with asthma, allergic sensitization, and Vitamin D Metabolites in asthmatic subjects.92while these PRELIMINARY results SUGGEST that Genetic components MAY account for Vitamin D status in subjects with asthma, OTHER STUDIES ARE NEEDED to determine tease out the Genetic vs. environmental UNDERPINNINGS of Vitamin D status in this population.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 21), ('ANOMALY_CURIOUS_FINDING', 39), ('INCOMPLETE_EVIDENCE', 225), ('SUPERFICIAL_RELATIONSHIP', 241), ('SUPERFICIAL_RELATIONSHIP', 287), ('SUPERFICIAL_RELATIONSHIP', 355), ('INCOMPLETE_EVIDENCE', 465), ('INCOMPLETE_EVIDENCE', 485), ('INCOMPLETE_EVIDENCE', 517), ('FUTURE_WORK', 575), ('FUTURE_WORK', 581), ('SUPERFICIAL_RELATIONSHIP', 653)]	13	[('SO_0000704', 'gene', 61, 'genes'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('SO_0001024', 'haplotype', 231, 'haplotype'), ('PR_000006101', 'cytochrome P450 1A1', 258, 'CYP24A1'), ('CHEBI_17933', 'calcidiol', 303, 'calcidiol'), ('GO_0008152', 'metabolic process', 313, 'metabolism'), ('SO_0001024', 'haplotype', 341, 'haplotype'), ('CHEBI_27300', 'vitamin D', 407, 'vitamin D'), ('CHEBI_25212', 'metabolite', 417, 'metabolites'), ('SO_0000704', 'gene', 498, 'genetic'), ('CHEBI_27300', 'vitamin D', 533, 'vitamin D'), ('SO_0000704', 'gene', 627, 'genetic'), ('CHEBI_27300', 'vitamin D', 670, 'vitamin D')]
S40-PMC3465343	PMC3465343	10/2012	S40-PMC3465343	['ra is a derivative of Vitamin A and is REQUIRED for synchronous left-right Development Of Somites, either maternal vad during Pregnancy or an Embryonic defect in Metabolism from Vitamin A to ra MIGHT be ASSOCIATED with increased risk of Human vertebral defects.']	[('IMPORTANT_CONSIDERATION', 39), ('INCOMPLETE_EVIDENCE', 194), ('SUPERFICIAL_RELATIONSHIP', 203)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin A'), ('GO_0042461', 'photoreceptor cell development', 75, 'development of somites'), ('UBERON_0002329', 'somite', 90, 'somites'), ('GO_0007565', 'female pregnancy', 126, 'pregnancy'), ('UBERON_0000922', 'embryo', 142, 'embryonic'), ('GO_0008152', 'metabolic process', 162, 'metabolism'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin A'), ('NCBITaxon_9606', 'Homo sapiens', 237, 'human')]
S93-PMC3470091	PMC3470091	9/2012	S93-PMC3470091	['moreover, additional clinical trial STUDIES will HAVE TO BE CONDUCTED to determine the EFFECT of mega doses of Vitamin D on other health-related parameters such as the FACTORS RELATED to Metabolic syndrome as well as inflammatory MARKERS.']	[('FUTURE_WORK', 36), ('SUPERFICIAL_RELATIONSHIP', 87), ('SUPERFICIAL_RELATIONSHIP', 168), ('SUPERFICIAL_RELATIONSHIP', 176), ('SUPERFICIAL_RELATIONSHIP', 230)]	5	[('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('GO_0008152', 'metabolic process', 187, 'metabolic')]
S16-PMC3476426	PMC3476426	8/2012	S16-PMC3476426	['the main Metabolic EFFECT of 1, 25 Dihydroxy Vitamin D3, which is MEDIATED through the INTERACTION with Vitamin D receptors, is promoting the Intestinal absorption and Renal Resorption Of Calcium in order to increase its circulating levels.']	[('SUPERFICIAL_RELATIONSHIP', 19), ('SUPERFICIAL_RELATIONSHIP', 66), ('SUPERFICIAL_RELATIONSHIP', 87)]	3	[('GO_0008152', 'metabolic process', 9, 'metabolic'), ('CHEBI_50341', '1-hydroxyethyl group', 29, '1, 25 dihydroxy'), ('CHEBI_33279', 'vitamin D5', 45, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 45, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('UBERON_0000160', 'intestine', 142, 'intestinal'), ('UBERON_0002113', 'kidney', 168, 'renal'), ('GO_0051201', 'negative regulation of prosthetic group metabolic process', 174, 'resorption of calcium')]
S177-PMC3515553	PMC3515553	12/2012	S177-PMC3515553	['caption (supplementary-material): table s3\n\nASSOCIATION of offspring genotype at Snps RELATED to Vitamin B-12 Metabolism with Vitamin B-12 Cord Blood concentration.']	[('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 86)]	2	[('SO_0000694', 'SNP', 81, 'SNPs'), ('CHEBI_70326', 'guttiferone A, (rel-(+))-', 97, 'vitamin B-'), ('GO_0000010', 'trans-hexaprenyltranstransferase activity', 97, 'vitamin B-12'), ('PR_000017269', 'ventral anterior homeobox 2', 97, 'vitamin B-12'), ('GO_0008152', 'metabolic process', 110, 'metabolism'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 126, 'vitamin B-12'), ('UBERON_0002240', 'spinal cord', 139, 'cord'), ('UBERON_0000178', 'blood', 144, 'blood')]
S218-PMC3515887	PMC3515887	11/2012	S218-PMC3515887	['Ascorbic Acid\nthe RATIONALE for Ascorbic Acid (Vitamin C) supplementation in large doses is that it blocks binding to da receptors and POSSIBLY corrects redox balance, leading to correction of Metabolic stress that MAY CONTRIBUTE to autism symptoms.']	[('INCOMPLETE_EVIDENCE', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('INCOMPLETE_EVIDENCE', 135), ('INCOMPLETE_EVIDENCE', 215), ('SUPERFICIAL_RELATIONSHIP', 219)]	5	[('CHEBI_2878', 'Aspecioside', 0, 'Ascorbic Acid'), ('CHEBI_22652', 'ascorbic acid', 32, 'ascorbic acid'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin C'), ('GO_0008152', 'metabolic process', 193, 'metabolic')]
S5-PMC3613945	PMC3613945	2/2013	S5-PMC3613945	['indeed, dbp and Vitamin D MAY JOINTLY OR INDEPENDENTLY CONTRIBUTE to a variety of adverse health outcomes unrelated to classical notions of their function in bone and Mineral Metabolism.']	[('INCOMPLETE_EVIDENCE', 26), ('SUPERFICIAL_RELATIONSHIP', 30), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 38), ('SUPERFICIAL_RELATIONSHIP', 41), ('SUPERFICIAL_RELATIONSHIP', 55)]	5	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_46662', 'mineral', 167, 'mineral'), ('GO_0008152', 'metabolic process', 175, 'metabolism')]
S12-PMC3613945	PMC3613945	2/2013	S12-PMC3613945	['the functions of dbp are STILL BEING DEFINED, but they include the Transport Of Vitamin D and its Metabolites in the circulation5,6, as well as actin scavenging and Fatty Acid binding7–12.']	[('FULL_UNKNOWN', 25)]	1	[('GO_0006415', 'translational termination', 67, 'transport of vitamin D'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 88, 'D'), ('CHEBI_25212', 'metabolite', 98, 'metabolites'), ('GO_0008152', 'metabolic process', 98, 'metabolites'), ('CHEBI_35366', 'fatty acid', 165, 'fatty acid'), ('GO_0019401', 'alditol biosynthetic process', 171, 'acid')]
S60-PMC3613945	PMC3613945	2/2013	S60-PMC3613945	['Vitamin D, dbp and Innate Immunity – an EMERGING theme\nthe ROLE of dbp in the biology of Vitamin D as it RELATES to the Endocrine status of bone and Mineral Metabolism is well established and the reader is referred to reviews47,48, monographs49and authoritative web sites50.']	[('INCOMPLETE_EVIDENCE', 40), ('SUPERFICIAL_RELATIONSHIP', 59), ('SUPERFICIAL_RELATIONSHIP', 105)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('GO_0045087', 'innate immune response', 19, 'innate immunity'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0006397', 'mRNA processing', 120, 'endocrine'), ('CHEBI_46662', 'mineral', 149, 'mineral'), ('GO_0008152', 'metabolic process', 157, 'metabolism')]
S38-PMC3659910	PMC3659910	1/2013	S38-PMC3659910	['[8] the active form of Vitamin D (1,25-Dihydroxyvitamin D3, 1,25[Oh] 2D3) has WELL-ESTABLISHED EFFECTS on bone Metabolism and Mineral Homeostasis.']	[('PROBABLE_UNDERSTANDING', 78), ('SUPERFICIAL_RELATIONSHIP', 95)]	2	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_63912', '19-hydroxyprostaglandin H2', 34, '1,25-dihydroxyvitamin D3'), ('CHEBI_64115', '(1S,2R)-5-methoxy-1-methyl-2-(propylamino)tetralin hydrochloride', 62, '25[OH] 2D3'), ('GO_0008152', 'metabolic process', 111, 'metabolism'), ('CHEBI_46662', 'mineral', 126, 'mineral'), ('GO_0055085', 'transmembrane transport', 126, 'mineral homeostasis')]
S55-PMC3659910	PMC3659910	1/2013	S55-PMC3659910	['[12] Vitamin D deficiency CAN result in lower bone Mineral density and an INCREASED RISK of bone loss (osteoporosis) or bone fracture BECAUSE a lack of Vitamin D alters Mineral Metabolism in the body.']	[('INCOMPLETE_EVIDENCE', 26), ('IMPORTANT_CONSIDERATION', 74), ('PROBABLE_UNDERSTANDING', 134)]	3	[('CHEBI_28384', 'vitamin K', 5, 'Vitamin D'), ('CHEBI_46662', 'mineral', 51, 'mineral'), ('CHEBI_27300', 'vitamin D', 152, 'vitamin D'), ('CHEBI_46662', 'mineral', 169, 'mineral'), ('GO_0008152', 'metabolic process', 177, 'metabolism')]
S2-PMC3668200	PMC3668200	5/2013	S2-PMC3668200	['many Genetic, dietary, and environmental FACTORS AFFECT the body concentration of Vitamin D, Calcium, Phosphorus, and Bone Metabolism.']	[('SUPERFICIAL_RELATIONSHIP', 41), ('SUPERFICIAL_RELATIONSHIP', 49)]	2	[('SO_0000704', 'gene', 5, 'genetic'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 93, 'calcium'), ('CHEBI_35885', 'secondary phosphine', 102, 'phosphorus'), ('GO_0007567', 'parturition', 118, 'bone'), ('GO_0008152', 'metabolic process', 123, 'metabolism')]
S51-PMC3668200	PMC3668200	5/2013	S51-PMC3668200	['MANY RESEARCH REPORTS on Vitamin D, which is IMPORTANT for Bony Metabolism and immunity, and has beneficial EFFECTS on diverse Organs, HAVE BEEN published RECENTLY.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 14), ('IMPORTANT_CONSIDERATION', 45), ('SUPERFICIAL_RELATIONSHIP', 108), ('INCOMPLETE_EVIDENCE', 135), ('INCOMPLETE_EVIDENCE', 155)]	6	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('UBERON_0001461', 'elbow', 59, 'bony'), ('GO_0008152', 'metabolic process', 64, 'metabolism'), ('UBERON_0000062', 'organ', 127, 'organs')]
S104-PMC3685533	PMC3685533	6/2013	S104-PMC3685533	['lob had lower Serum levels with respect to Mbb, SUGGESTING a particular ROLE for different skin colour in Metabolism and in Vitamin D levels.']	[('INCOMPLETE_EVIDENCE', 48), ('SUPERFICIAL_RELATIONSHIP', 72)]	2	[('UBERON_0001977', 'blood serum', 14, 'serum'), ('PR_000010211', 'protein max', 43, 'MBB'), ('GO_0008152', 'metabolic process', 106, 'metabolism'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]
S51-PMC3695234	PMC3695234	7/2013	S51-PMC3695234	['ALTHOUGH there was no healthy control group, OUR FINDINGS SHOWED lower normal levels of Serum Vitamin D (15.61±5.67 ng/ml) irrespective of ad severity, which SUGGESTS a CORRELATION between ad and the absorption and Metabolism Of Vitamin D.\nthis Metabolism begins with two processes: absorption into the skin as Vitamin D3And via the Gut as either Vitamin D2Or Vitamin D3.']	[('ANOMALY_CURIOUS_FINDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 45), ('INCOMPLETE_EVIDENCE', 58), ('INCOMPLETE_EVIDENCE', 158), ('SUPERFICIAL_RELATIONSHIP', 169)]	5	[('UBERON_0001977', 'blood serum', 88, 'serum'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('GO_0019458', 'methionine catabolic process via 2-oxobutanoate', 215, 'metabolism of vitamin D'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('GO_0008152', 'metabolic process', 245, 'metabolism'), ('CHEBI_61991', 'maltotriose trisaccharide', 311, 'vitamin D3and'), ('PR_000027594', 'histone H3', 311, 'vitamin D3and'), ('UBERON_0001555', 'digestive tract', 333, 'gut'), ('CHEBI_27329', 'xanthosine phosphate', 347, 'vitamin D2or'), ('PR_000017209', 'utrophin', 347, 'vitamin D2or'), ('CHEBI_33279', 'vitamin D5', 360, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 360, 'vitamin D3')]
S52-PMC3695234	PMC3695234	7/2013	S52-PMC3695234	['these Molecules are then Metabolized in the Liver to 25(Oh) Vitamin D, the Vitamin D pro-hormone, which is USUALLY used to measure Vitamin d levels clinically.']	[('INCOMPLETE_EVIDENCE', 107)]	1	[('CHEBI_36357', 'polyatomic entity', 6, 'molecules'), ('GO_0008152', 'metabolic process', 25, 'metabolized'), ('UBERON_0002107', 'liver', 44, 'liver'), ('CHEBI_30778', 'gallic acid', 53, '25(OH)'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 131, 'vitamin')]
S53-PMC3695234	PMC3695234	7/2013	S53-PMC3695234	['this Molecule is subsequently Metabolized in the Kidney to its active form, 1,25(Oh)2D3, which plays a key ROLE in Skeletal and Extraskeletal functions, including immunity and Glucose Metabolism.8since it is absorbed via the skin, the IMPACT of Vitamin D levels on allergic skin diseases is of particular interest.']	[('SUPERFICIAL_RELATIONSHIP', 107), ('SUPERFICIAL_RELATIONSHIP', 235)]	2	[('CHEBI_36357', 'polyatomic entity', 5, 'molecule'), ('GO_0008152', 'metabolic process', 30, 'metabolized'), ('UBERON_0002113', 'kidney', 49, 'kidney'), ('CHEBI_37983', 'sulfur-35 atom', 76, '1'), ('CHEBI_17996', 'chloride', 77, ','), ('CHEBI_73394', 'Ala-Ser', 78, '25(OH)2D3'), ('UBERON_0004288', 'skeleton', 115, 'skeletal'), ('UBERON_0001431', 'distal carpal bone 2', 128, 'extraskeletal'), ('CHEBI_17234', 'glucose', 176, 'glucose'), ('GO_0006006', 'glucose metabolic process', 176, 'glucose metabolism'), ('CHEBI_27300', 'vitamin D', 245, 'vitamin D')]
S5-PMC3702245	PMC3702245	6/2013	S5-PMC3702245	['ALTHOUGH the Synthesis and Metabolism Of Vitamin D in the nonpregnant state is WELL KNOWN, its Metabolism during Pregnancy is LESS WELL UNDERSTOOD.3the classical action of vitamin d is to maintain Calcium Homeostasis and bone health.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 79), ('INCOMPLETE_EVIDENCE', 126)]	3	[('GO_0007416', 'synapse assembly', 13, 'synthesis ...'), ('GO_0019458', 'methionine catabolic process via 2-oxobutanoate', 27, 'metabolism of vitamin D'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0008152', 'metabolic process', 95, 'metabolism'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('GO_0055073', 'cadmium ion homeostasis', 197, 'calcium homeostasis')]
S13-PMC3717170	PMC3717170	5/2013	S13-PMC3717170	['nonclassical EFFECTS of Vitamin D\n\nVitamin D: beyond bone\nsylvia christakos (umdnj-new jersey medical school) began the meeting by summarizing the Metabolism and activity of Vitamin D and introducing the EMERGING AWARENESS of ROLES for Vitamin D beyond Calcium Homeostasis and Bone Metabolism.']	[('SUPERFICIAL_RELATIONSHIP', 13), ('INCOMPLETE_EVIDENCE', 204), ('IMPORTANT_CONSIDERATION', 213), ('SUPERFICIAL_RELATIONSHIP', 226)]	4	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 35, 'Vitamin D'), ('GO_0008152', 'metabolic process', 147, 'metabolism'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 236, 'vitamin D'), ('GO_0055073', 'cadmium ion homeostasis', 253, 'calcium homeostasis'), ('GO_0006768', 'biotin metabolic process', 277, 'bone metabolism')]
S141-PMC3717170	PMC3717170	5/2013	S141-PMC3717170	['the results from SMALL clinical trials and post hoc analyses of larger trials on the EFFECT of Vitamin D supplementation on diabetes-related parameters HAVE BEEN INCONCLUSIVE, although Vitamin D APPEARS to have beneficial EFFECTS in Persons AT RISK for diabetes.36–39HOWEVER, no firm conclusions can be drawn from the available intervention studies BECAUSE of several LIMITATIONS: (1) NEARLY ALL studies were UNDERPOWERED; (2) the MINORITY of studies were designed specifically for Glycemic outcomes; (3) MOST STUDIES DID NOT REPORT use of diabetes medications at baseline or during the study; (4) SOME TRIALS used large infrequent doses of Vitamin D, which MAY BE Metabolized DIFFERENTLY compared to daily doses and MAY provide EITHER no benefit OR result in an UNFAVORABLE benefit/risk ratio.']	[('INCOMPLETE_EVIDENCE', 17), ('SUPERFICIAL_RELATIONSHIP', 85), ('INCOMPLETE_EVIDENCE', 152), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 162), ('ANOMALY_CURIOUS_FINDING', 195), ('SUPERFICIAL_RELATIONSHIP', 222), ('IMPORTANT_CONSIDERATION', 241), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 265), ('PROBLEM_COMPLICATION', 349), ('INCOMPLETE_EVIDENCE', 368), ('PROBLEM_COMPLICATION', 368), ('PROBABLE_UNDERSTANDING', 385), ('PROBLEM_COMPLICATION', 409), ('INCOMPLETE_EVIDENCE', 431), ('INCOMPLETE_EVIDENCE', 505), ('INCOMPLETE_EVIDENCE', 518), ('INCOMPLETE_EVIDENCE', 598), ('INCOMPLETE_EVIDENCE', 658), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 677), ('INCOMPLETE_EVIDENCE', 717), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 729), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 747), ('IMPORTANT_CONSIDERATION', 763)]	23	[('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 185, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 233, 'persons'), ('GO_0006096', 'glycolytic process', 482, 'glycemic'), ('CHEBI_27300', 'vitamin D', 641, 'vitamin D'), ('GO_0008152', 'metabolic process', 665, 'metabolized')]
S21-PMC3827489	PMC3827489	10/2013	S21-PMC3827489	['the wide variety of nonskeletal diseases in which Vitamin D is IMPORTANT include Cardiovascular diseases3), obesity4), Metabolic syndrome5), Insulin resistance6), infection7), allergy8,9), some forms of cancers10-12), and Autoimmune diseases13).']	[('IMPORTANT_CONSIDERATION', 63)]	1	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('UBERON_0004535', 'cardiovascular system', 81, 'cardiovascular'), ('GO_0008152', 'metabolic process', 119, 'metabolic'), ('PR_000045358', 'insulin family protein', 141, 'insulin'), ('UBERON_0001442', 'skeleton of manus', 222, 'autoimmune')]
S87-PMC3827489	PMC3827489	10/2013	S87-PMC3827489	['taken TOGETHER, THESE FINDINGS SUGGEST that PUBLIC HEALTH INTERVENTIONS such as outdoor activity and Vitamin D supplementation, which enhance Vitamin D status, MAY improve the health of adolescents with Metabolic PROBLEMS.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 31), ('IMPORTANT_CONSIDERATION', 44), ('FUTURE_WORK', 58), ('INCOMPLETE_EVIDENCE', 160), ('IMPORTANT_CONSIDERATION', 213)]	7	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('GO_0008152', 'metabolic process', 203, 'metabolic')]
S115-PMC3855580	PMC3855580	10/2013	S115-PMC3855580	['in the ONLY data from a randomised controlled trial, children of women in nepal who were supplemented with Vitamin A plus Folic Acid from early Gestation had less microalbuminuria and a lower prevalence of Metabolic syndrome at 6–8\xa0years than children of mothers supplemented with Vitamin A alone [29].']	[('INCOMPLETE_EVIDENCE', 7)]	1	[('CHEBI_27300', 'vitamin D', 107, 'vitamin A'), ('CHEBI_30751', 'formic acid', 122, 'folic acid'), ('GO_0007565', 'female pregnancy', 144, 'gestation'), ('GO_0008152', 'metabolic process', 206, 'metabolic'), ('CHEBI_27300', 'vitamin D', 281, 'vitamin A')]
S12-PMC3888066	PMC3888066	12/2012	S12-PMC3888066	['this NOTION is BASED ON the KNOWN Teratogenic EFFECTS of Retinoic Acids on the Central Nervous System,1–3the CALCULATED dose of Retinol and Beta Carotene Ingested by the mother during early Pregnancy, and STRONG EVIDENCE that the fetus Metabolizes Beta Carotene to Retinoids and has LIMITED ability to store Beta Carotene in Fat Cells.4–7\nin 1995, rothman et al DEMONSTRATED that high maternal dietary intake of Vitamin A in the form of Retinol, ie, >10,000 iu/day, particularly in the first Trimester, MAY BE ASSOCIATED with Cranial-Neural-Crest Birth defects.8using a smooth regression curve, THIS study of 22,748 Pregnant women and their offspring IDENTIFIED 1 infant in 57 with malformations that COULD BE ATTRIBUTED to the intake of supplements of Preformed Vitamin A at a dose >10,000 iu/day.']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 15), ('ANOMALY_CURIOUS_FINDING', 21), ('ANOMALY_CURIOUS_FINDING', 21), ('INCOMPLETE_EVIDENCE', 28), ('SUPERFICIAL_RELATIONSHIP', 46), ('INCOMPLETE_EVIDENCE', 109), ('INCOMPLETE_EVIDENCE', 205), ('INCOMPLETE_EVIDENCE', 283), ('INCOMPLETE_EVIDENCE', 362), ('INCOMPLETE_EVIDENCE', 503), ('SUPERFICIAL_RELATIONSHIP', 510), ('QUESTION_ANSWERED_BY_THIS_WORK', 595), ('INCOMPLETE_EVIDENCE', 651), ('INCOMPLETE_EVIDENCE', 701), ('SUPERFICIAL_RELATIONSHIP', 710)]	16	[('CHEBI_50905', 'teratogenic agent', 34, 'teratogenic'), ('CHEBI_26536', 'retinoic acid', 57, 'retinoic acids'), ('UBERON_0001017', 'central nervous system', 79, 'central nervous system'), ('CHEBI_26536', 'retinoic acid', 128, 'retinol'), ('CHEBI_51438', 'D-isoascorbic acid', 140, 'beta carotene'), ('GO_0007631', 'feeding behavior', 154, 'ingested'), ('GO_0007565', 'female pregnancy', 190, 'pregnancy'), ('GO_0008152', 'metabolic process', 236, 'metabolizes'), ('CHEBI_51438', 'D-isoascorbic acid', 248, 'beta carotene'), ('CHEBI_26537', 'retinoid', 265, 'retinoids'), ('CHEBI_51438', 'D-isoascorbic acid', 308, 'beta carotene'), ('CL_0000136', 'fat cell', 325, 'fat cells'), ('CHEBI_27300', 'vitamin D', 412, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 437, 'retinol'), ('GO_0009294', 'DNA mediated transformation', 492, 'trimester'), ('UBERON_0001456', 'face', 526, 'cranial'), ('UBERON_0002342', 'neural crest', 534, 'neural-crest'), ('GO_0007567', 'parturition', 547, 'birth'), ('GO_0007565', 'female pregnancy', 616, 'pregnant'), ('GO_0007565', 'female pregnancy', 753, 'preformed'), ('CHEBI_27300', 'vitamin D', 763, 'vitamin A')]
S45-PMC3888066	PMC3888066	12/2012	S45-PMC3888066	['examples of non-fortified Foods that are high in Vitamin A or beta Carotene are listed intable 5.37\n\ncalculation of Vitamin A and beta Carotene intake during Pregnancy\nthe absorption, Metabolism, storage, and Excretion Of Beta Carotene and Retinol in the mother are NOT COMPLETELY UNDERSTOOD; HOWEVER, most investigators agree that consumption of these forms of Vitamin A is RELATED to maternal Serum levels.38–40in ONE STUDY, maternal diet INFLUENCED Cord levels of Beta Carotene, but not Vitamin A.41absorption Of Beta Carotene from raw carrots and a low fat diet is very low compared to carrot juice.42according to current literature, 6 μg of Ingested Beta Carotene convert to 1 Retinol equivalent, or 1 μg Retinol, but ratios have ranged from 3.3:1 to 26:1.43,44\nbased on the discussion above, it MAY BE apparent that Maternal Ingestion of non-Beta Carotene sources of Vitamin A in foods + fortified foods + nutritional supplements would not LIKELY elevate Retinoic Acid levels in the fetus to Teratogenic levels.']	[('INCOMPLETE_EVIDENCE', 266), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 293), ('SUPERFICIAL_RELATIONSHIP', 375), ('INCOMPLETE_EVIDENCE', 416), ('SUPERFICIAL_RELATIONSHIP', 441), ('INCOMPLETE_EVIDENCE', 801), ('PROBABLE_UNDERSTANDING', 946)]	7	[('CHEBI_33290', 'food', 26, 'foods'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin A'), ('CHEBI_23042', 'carotene', 67, 'carotene'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin A'), ('CHEBI_23042', 'carotene', 135, 'carotene'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy'), ('GO_0008152', 'metabolic process', 184, 'metabolism'), ('GO_0007530', 'sex determination', 209, 'excretion of ... carotene'), ('CHEBI_51438', 'D-isoascorbic acid', 222, 'beta carotene'), ('CHEBI_26536', 'retinoic acid', 240, 'retinol'), ('GO_0060033', 'anatomical structure regression', 240, 'retinol'), ('CHEBI_27300', 'vitamin D', 362, 'vitamin A'), ('UBERON_0001977', 'blood serum', 395, 'serum'), ('UBERON_0002240', 'spinal cord', 452, 'cord'), ('CHEBI_51438', 'D-isoascorbic acid', 467, 'beta carotene'), ('CHEBI_27300', 'vitamin D', 490, 'vitamin A'), ('GO_0046311', 'prenylcysteine biosynthetic process', 513, 'of ... carotene'), ('CHEBI_51438', 'D-isoascorbic acid', 516, 'beta carotene'), ('GO_0007631', 'feeding behavior', 646, 'ingested'), ('CHEBI_51438', 'D-isoascorbic acid', 655, 'beta carotene'), ('CHEBI_26536', 'retinoic acid', 682, 'retinol'), ('CHEBI_26536', 'retinoic acid', 710, 'retinol'), ('GO_0007618', 'mating', 822, 'maternal'), ('GO_0007631', 'feeding behavior', 831, 'ingestion'), ('CHEBI_51438', 'D-isoascorbic acid', 848, 'beta carotene'), ('CHEBI_27300', 'vitamin D', 873, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 961, 'retinoic acid'), ('CHEBI_50905', 'teratogenic agent', 998, 'teratogenic'), ('GO_0031649', 'heat generation', 998, 'teratogenic')]
S36-PMC3973641	PMC3973641	4/2014	S36-PMC3973641	['considering that exposure to suboptimal nutrition during early development LEADS TO a long-term, age-DEPENDENT Metabolic response[26], we INVESTIGATED the EFFECTS of a Vitamin B-deficient diet during Pregnancy or Pregnancy/Lactation in Mice offspring.']	[('SUPERFICIAL_RELATIONSHIP', 75), ('SUPERFICIAL_RELATIONSHIP', 101), ('QUESTION_ANSWERED_BY_THIS_WORK', 138), ('SUPERFICIAL_RELATIONSHIP', 155)]	4	[('GO_0008152', 'metabolic process', 111, 'metabolic'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin B'), ('GO_0007565', 'female pregnancy', 200, 'pregnancy'), ('GO_0007565', 'female pregnancy', 213, 'pregnancy'), ('GO_0007595', 'lactation', 223, 'lactation'), ('NCBITaxon_10088', 'Mus <genus>', 236, 'mice')]
S24-PMC3991049	PMC3991049	11/2013	S24-PMC3991049	"[""a RECENT STUDY SHOWED that a daily supplement of 4000 iu of Vitamin D was REQUIRED to sustain normal Metabolism in Pregnancy and this dose was EFFECTIVE and SAFE.9\nin THIS STUDY we EVALUATED the prevalence of Vitamin D deficiency in Pregnant women and EVALUATED the EFFECT of weekly Oral 50,000 iu of Vitamin D on mothers' and newborn's level of Vitamin D.\n\nmethods\nTHIS is a prospective observational study conducted at a single center at hamad medical corporation in doha, qatar.""]"	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 74), ('SUPERFICIAL_RELATIONSHIP', 143), ('IMPORTANT_CONSIDERATION', 157), ('QUESTION_ANSWERED_BY_THIS_WORK', 167), ('QUESTION_ANSWERED_BY_THIS_WORK', 181), ('QUESTION_ANSWERED_BY_THIS_WORK', 252), ('SUPERFICIAL_RELATIONSHIP', 266), ('QUESTION_ANSWERED_BY_THIS_WORK', 366)]	10	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0008152', 'metabolic process', 101, 'metabolism'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D'), ('GO_0007565', 'female pregnancy', 233, 'pregnant'), ('UBERON_0000165', 'mouth', 283, 'oral'), ('CHEBI_27300', 'vitamin D', 301, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 346, 'vitamin D')]
S1-PMC4045304	PMC4045304	2/2014	S1-PMC4045304	['though both Genetic and multiple environmental RISK FACTORS HAVE BEEN studied extensively, many POTENTIALLY modifiable RISK factors including nutritional and Immune function RELATED RISK FACTORS such as Vitamin D, Folic Acid, and Metabolic syndrome have NOT RECEIVED SUFFICIENT ATTENTION.']	[('SUPERFICIAL_RELATIONSHIP', 47), ('INCOMPLETE_EVIDENCE', 60), ('INCOMPLETE_EVIDENCE', 96), ('SUPERFICIAL_RELATIONSHIP', 119), ('SUPERFICIAL_RELATIONSHIP', 174), ('SUPERFICIAL_RELATIONSHIP', 182), ('INCOMPLETE_EVIDENCE', 254)]	7	[('SO_0000704', 'gene', 12, 'genetic'), ('UBERON_0002405', 'immune system', 158, 'immune'), ('CHEBI_27300', 'vitamin D', 203, 'vitamin D'), ('CHEBI_30751', 'formic acid', 214, 'folic acid'), ('GO_0008152', 'metabolic process', 230, 'metabolic')]
S133-PMC4045304	PMC4045304	2/2014	S133-PMC4045304	['a GROWING body of LITERATURE SUGGESTS that certain modifiable RISK FACTORS such as maternal Metabolic syndrome and certain Vitamins such as Vitamin D and Folic Acid either in utero or early Life, MAY BE ASSOCIATED with increased risk of autism [43–45].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 29), ('SUPERFICIAL_RELATIONSHIP', 62), ('INCOMPLETE_EVIDENCE', 196), ('SUPERFICIAL_RELATIONSHIP', 203)]	5	[('GO_0008152', 'metabolic process', 92, 'metabolic'), ('CHEBI_33277', 'gamma-tocotrienol', 123, 'vitamins'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('CHEBI_30751', 'formic acid', 154, 'folic acid'), ('UBERON_0000104', 'life cycle', 190, 'life')]
S266-PMC4045304	PMC4045304	2/2014	S266-PMC4045304	['furthermore, OTHER modifiable, nutrition related RISK factors such as Folic Acid, Vitamin D, and maternal Metabolic syndrome MAY ACCOUNT FOR SOME proportion of increase in asd prevalence.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 13), ('SUPERFICIAL_RELATIONSHIP', 49), ('INCOMPLETE_EVIDENCE', 125), ('PROBABLE_UNDERSTANDING', 129), ('INCOMPLETE_EVIDENCE', 141)]	5	[('CHEBI_30751', 'formic acid', 70, 'folic acid'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0008152', 'metabolic process', 106, 'metabolic')]
S850-PMC4113768	PMC4113768	7/2014	S850-PMC4113768	['background: the ROLE of Vitamin D in bone Metabolism is WELL KNOWN BUT its’ actions on muscle are INCOMPLETELY understood.']	[('SUPERFICIAL_RELATIONSHIP', 16), ('INCOMPLETE_EVIDENCE', 56), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 67), ('INCOMPLETE_EVIDENCE', 98)]	4	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0008152', 'metabolic process', 42, 'metabolism')]
S1072-PMC4113768	PMC4113768	7/2014	S1072-PMC4113768	['methods: we determined concentrations of Serum 25 Hydroxy-Vitamin D in RELATION to several other Metabolic BIOMARKERS including total Cholesterol, low-density lipoprotein Cholesterol (ldl-c), high density lipoprotein-Cholesterol (Hdl-C), Triglycerides, atherogenic index, Glucose, C-Reactive Protein (crp), measures of adiposity, and Blood pressure values in a cross-sectional analysis in 180 saudi Postmenopausal women aged 48 to 88 years.']	[('SUPERFICIAL_RELATIONSHIP', 71), ('SUPERFICIAL_RELATIONSHIP', 107)]	2	[('UBERON_0001977', 'blood serum', 41, 'serum'), ('CHEBI_67778', '(E)-Adrienyne, [rel(threo)]-', 47, '25 hydroxy-'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('GO_0008152', 'metabolic process', 97, 'metabolic'), ('CHEBI_16113', 'cholesterol', 134, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 171, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 217, 'cholesterol'), ('PR_000008530', 'hairy/enhancer-of-split related with YRPW motif-like protein', 230, 'HDL-C'), ('CHEBI_17855', 'triglyceride', 238, 'triglycerides'), ('CHEBI_17234', 'glucose', 272, 'glucose'), ('PR_000005890', 'crooked neck-like protein 1', 281, 'C-reactive protein'), ('UBERON_0000178', 'blood', 334, 'blood'), ('GO_0007595', 'lactation', 399, 'postmenopausal')]
S2303-PMC4113768	PMC4113768	7/2014	S2303-PMC4113768	['in THIS cross-SECTIONAL case-CONTROL STUDY, we DESCRIBED the differences and ASSOCIATIONS in the Metabolic patterns of Adult saudis with and without hypothyroid dysfunction in RELATION to their Vitamin D status, pth, calcium and Lipid profile.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('INCOMPLETE_EVIDENCE', 47), ('SUPERFICIAL_RELATIONSHIP', 77), ('SUPERFICIAL_RELATIONSHIP', 176)]	6	[('GO_0008152', 'metabolic process', 97, 'metabolic'), ('UBERON_0007023', 'adult organism', 119, 'adult'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('CHEBI_18059', 'lipid', 229, 'lipid')]
S2334-PMC4113768	PMC4113768	7/2014	S2334-PMC4113768	['in THIS PROSPECTIVE INTERVENTIONAL STUDY we INVESTIGATED the EFFECTS of Vitamin D3Supplementation on the Metabolic profiles of saudi t2dm subjects pre- and post-Vitamin D supplementation over an 18-month period.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 20), ('QUESTION_ANSWERED_BY_THIS_WORK', 44), ('SUPERFICIAL_RELATIONSHIP', 61)]	4	[('CHEBI_52915', 'phosphatediyl group', 72, 'vitamin D3supplementation'), ('PR_000006649', 'zinc finger protein neuro-d4', 80, 'D3supplementation'), ('GO_0008152', 'metabolic process', 105, 'metabolic'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D')]
S2358-PMC4113768	PMC4113768	7/2014	S2358-PMC4113768	['in THIS FOLLOW-UP STUDY we DETERMINED seasonal differences in Serum 25(Oh)D Vitamin D levels, as well as parallel changes in Metabolic parameters, in a cohort of Adult overweight and obese saudis.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 8), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 27)]	4	[('UBERON_0001977', 'blood serum', 62, 'serum'), ('CHEBI_71657', 'versiconol acetate', 68, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0008152', 'metabolic process', 125, 'metabolic'), ('UBERON_0007023', 'adult organism', 162, 'adult')]
S2616-PMC4113768	PMC4113768	7/2014	S2616-PMC4113768	['we INVESTIGATED the EFFECT of Vitamin D supplementation on the Metabolic status of Individuals at increased risk of developing t2d.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 20)]	2	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0008152', 'metabolic process', 63, 'metabolic'), ('NCBITaxon_1', 'root', 83, 'individuals')]
S3300-PMC4113768	PMC4113768	7/2014	S3300-PMC4113768	['there are many mechanisms whereby Vitamin D CAN reduce the RISK of cvd including reduced risk of diabetes mellitus and Metabolic syndrome, EFFECTS on Blood pressure, Cholesterol, cytokines, Endothelial disruption, Glucose Regulation, Insulin resistance, muscle strength, Respiratory infections, and vascular calcification.']	[('INCOMPLETE_EVIDENCE', 44), ('IMPORTANT_CONSIDERATION', 59), ('SUPERFICIAL_RELATIONSHIP', 139)]	3	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0008152', 'metabolic process', 119, 'metabolic'), ('UBERON_0000178', 'blood', 150, 'blood'), ('CHEBI_16113', 'cholesterol', 166, 'cholesterol'), ('UBERON_0001986', 'endothelium', 190, 'endothelial'), ('CHEBI_17234', 'glucose', 214, 'glucose'), ('GO_0006094', 'gluconeogenesis', 214, 'glucose regulation'), ('PR_000045358', 'insulin family protein', 234, 'insulin'), ('UBERON_0001004', 'respiratory system', 271, 'respiratory')]
S66-PMC4188019	PMC4188019	1/2010	S66-PMC4188019	['with NEW date on the ROLE of Vitamin D besides bone Metabolism, SOME authors are PLEADING for higher cut-off values to determine deficiency (norman et al., 2007; sachan et al., 2005; wagner et al., 2008).']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 21), ('INCOMPLETE_EVIDENCE', 64), ('IMPORTANT_CONSIDERATION', 81), ('IMPORTANT_CONSIDERATION', 81)]	5	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0008152', 'metabolic process', 52, 'metabolism')]
S27-PMC4302429	PMC4302429	1/2015	S27-PMC4302429	['cells of the Immune System possess Vitamin D receptors and are capable of Metabolizing the active form of Vitamin D (1,25(Oh)2D3) [15], SUGGESTING Vitamin D as an IMPORTANT FACTOR in the Immune Response to Infection [16].']	[('INCOMPLETE_EVIDENCE', 136), ('IMPORTANT_CONSIDERATION', 163), ('SUPERFICIAL_RELATIONSHIP', 173)]	3	[('UBERON_0002405', 'immune system', 13, 'immune system'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0008152', 'metabolic process', 74, 'metabolizing'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('CHEBI_72779', '11-trans-LTE4', 117, '1,25(OH)2D3'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('GO_0006955', 'immune response', 187, 'immune response'), ('UBERON_0002405', 'immune system', 187, 'immune'), ('GO_0007586', 'digestion', 206, 'infection')]
S133-PMC4303849	PMC4303849	1/2015	S133-PMC4303849	['25Ohd values lesser than 50 nmol/l MAY sustain long-term adverse health consequences and are classified as “deficiency.” the 75 nmol/l cut-off is the point above which there is no upper stimulation of pth [102] and was thereafter designated as “sufficient.” HOWEVER, heaney POINTED out that 25Ohd concentrations < 80 nmol/l are ASSOCIATED with reduced calcium absorption and osteoporosis risk [103]; therefore, values lesser than 75 nmol/l are considered AS “insufficient.” the conversion factor between 25Ohd nmol/l and ng/ml is 2.5 (table 2).nutrients-07-00443-t001_table 1\n\ncaption (table-wrap): table 1\n\ntargets Modulated by Calcitriol in the Human Placenta (+ = stimulation; − = inhibition).targetbiological networkregulationbioeffectcell typereferenceplacental Lactogencell Life and death+growth controltrophoblast[97]Tnf-Αimmune function−restraining inflammationtrophoblast[91,92]−immunosupressiondecidual cells[89]Il-6Immune function−restraining inflammationtrophoblast[91,92]−immunosupressiondecidual cells[89]Csf2 (Colony Stimulating Factor 2)immune function−immunosupressiondecidual Cells[89]hctdimmune function+restraining infectiontrophoblast[90]Decidual Cells[89]Cyp24A1Bone and Mineral Metabolism+Calcitriol Catabolismtrophoblast[12]Decidual Cells[104]Cyp27B1Bone and Mineral Metabolism−Calcitriol synthesistrophoblast[12]Il-10 (Interleukin 10)immune function−reducing risk of infectiontrophoblast[105]Kcnh1 (potassium voltage-Gated channel)Cell Life and Death−unknowntrophoblast[106]Calbindin-D 28 kdabone and Mineral Metabolism+Calcium transfertrophoblast[61,62]Calbindin-D 9 kdabone and Mineral Metabolism+Calcium transfertrophoblast[61]hcg (Human Chorionic Gonadotrophin)Cell Life and Death+, −maintenance of Pregnancytrophoblast[96]3β-hsd (3Β-Hydroxysteroid dehydrogenase) *Cell Life and Death+Progesterone Synthesistrophoblast[95]Cyp19 (aromatase) *Cell Life and Death+Estradiol Synthesistrophoblast[95]Prolactincell Life and Death+Establishment Of Pregnancydecidual Cells[107]Vdrbone and Mineral Metabolism+allowing Calcitriol actionstrophoblast[62]Platelet-Activating factor acetylhydrolasecell life and Death−inactivation of Platelet-Activating factordecidual Macrophages[108]Hoxa10 (Homeobox A10)Cell Life and Death+Embryo Implantationdecidual cells[109]Osteopontinbone and Mineral Metabolism+Embryo Implantationdecidual Cells[104]Hbd2Immune function+restraining infectiontrophoblast[93]Hbd3Immune function+restraining infectiontrophoblast[93]\n* only observed at the enzyme activity level.nutrients-07-00443-t002_table 2\n\ncaption (table-wrap): table 2\n\ncut-offs in Vitamin D status according to the Endocrine society [110].Vitamin D status25ohd (nmol/l)25Ohd (ng/ml)severe deficiency<25<10deficiency<50<20insufficiency<75<30sufficiency75–11030–44toxicity>250>100\ntable 2shows the criteria for vd status as PROPOSED by the Endocrine society.']	[('INCOMPLETE_EVIDENCE', 35), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 258), ('INCOMPLETE_EVIDENCE', 274), ('SUPERFICIAL_RELATIONSHIP', 328), ('PROBABLE_UNDERSTANDING', 455), ('INCOMPLETE_EVIDENCE', 2831)]	6	"[('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 0, '25OHD'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 291, '25OHD'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 504, '25OHD'), ('GO_0065007', 'biological regulation', 616, 'modulated'), ('CHEBI_17823', 'calcitriol', 629, 'calcitriol'), ('NCBITaxon_9606', 'Homo sapiens', 647, 'human'), ('UBERON_0001987', 'placenta', 653, 'placenta'), ('CHEBI_35417', 'alpha-amino-acid residue radical', 767, 'lactogenCell'), ('PR_000009797', 'LIM/homeobox protein Lhx9', 767, 'lactogenCell'), ('UBERON_0000104', 'life cycle', 780, 'life'), ('PR_000000045', 'S-phase kinase-associated protein 1A', 824, 'TNF-αImmune'), ('PR_000008988', 'interleukin-1 family member 5', 922, 'IL-6Immune'), ('PR_000005890', 'crooked neck-like protein 1', 1019, 'CSF2'), ('PR_000005528', 'chloride channel protein, skeletal muscle', 1025, 'colony stimulating factor 2'), ('CL_0000573', 'retinal cone cell', 1094, 'cells'), ('CL_0000635', ""Deiter's cell"", 1159, 'Decidual cells'), ('PR_000006081', 'NADH-cytochrome b5 reductase 2', 1177, 'CYP24A1Bone'), ('CHEBI_46662', 'mineral', 1193, 'mineral'), ('GO_0008152', 'metabolic process', 1201, 'metabolism'), ('CHEBI_17823', 'calcitriol', 1212, 'Calcitriol'), ('GO_0019065', 'receptor-mediated endocytosis of virus by host cell', 1212, 'Calcitriol catabolismTrophoblast'), ('CL_0000635', ""Deiter's cell"", 1248, 'Decidual cells'), ('PR_000006081', 'NADH-cytochrome b5 reductase 2', 1267, 'CYP27B1Bone'), ('CHEBI_46662', 'mineral', 1283, 'mineral'), ('GO_0008152', 'metabolic process', 1291, 'metabolism'), ('CHEBI_17823', 'calcitriol', 1302, 'Calcitriol'), ('PR_000001470', 'interleukin-28B', 1337, 'IL-10'), ('PR_000001470', 'interleukin-28B', 1344, 'Interleukin 10'), ('PR_000000793', 'voltage-gated potassium channel KCNH4', 1417, 'KCNH1'), ('PR_000004587', 'beta-1,3-galactosyltransferase 6', 1441, '-gated'), ('GO_0008219', 'cell death', 1456, 'Cell life ... death'), ('PR_000004968', 'calretinin', 1499, 'Calbindin-D 28'), ('CHEBI_46662', 'mineral', 1526, 'mineral'), ('GO_0008152', 'metabolic process', 1534, 'metabolism'), ('CHEBI_31341', 'calcium dihydroxide', 1545, 'Calcium'), ('PR_000004998', 'calmodulin-regulated spectrin-associated protein 1', 1579, 'Calbindin-D'), ('CHEBI_46662', 'mineral', 1605, 'mineral'), ('GO_0008152', 'metabolic process', 1613, 'metabolism'), ('CHEBI_31341', 'calcium dihydroxide', 1624, 'Calcium'), ('NCBITaxon_9606', 'Homo sapiens', 1660, 'human'), ('PR_000005170', 'CD37 molecule', 1666, 'chorionic gonadotrophin'), ('UBERON_0003124', 'chorion', 1666, 'chorionic'), ('GO_0008219', 'cell death', 1690, 'Cell life ... death'), ('GO_0006412', 'translation', 1728, 'pregnancyTrophoblast'), ('CHEBI_36864', '25-hydroxy steroid', 1760, '3β-hydroxysteroid'), ('GO_0008219', 'cell death', 1794, 'Cell life ... death'), ('UBERON_0000104', 'life cycle', 1799, 'life'), ('CHEBI_17026', 'progesterone', 1814, 'Progesterone'), ('GO_0072598', 'protein localization to chloroplast', 1814, 'Progesterone synthesisTrophoblast'), ('PR_000006100', 'aromatase', 1851, 'CYP19'), ('GO_0008219', 'cell death', 1870, 'Cell life ... death'), ('UBERON_0000104', 'life cycle', 1875, 'life'), ('CHEBI_4856', 'esmolol', 1890, 'Estradiol'), ('GO_0072596', 'establishment of protein localization to chloroplast', 1890, 'Estradiol synthesisTrophoblast'), ('PR_000013039', 'POU domain, class 3, transcription factor 2', 1924, 'ProlactinCell'), ('GO_0006266', 'DNA ligation', 1938, 'life ... death'), ('GO_0006884', 'cell volume homeostasis', 1953, 'Establishment of pregnancyDecidual cells'), ('CL_0000573', 'retinal cone cell', 1988, 'cells'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1998, 'VDRBone'), ('CHEBI_46662', 'mineral', 2010, 'mineral'), ('GO_0008152', 'metabolic process', 2018, 'metabolism'), ('CHEBI_17823', 'calcitriol', 2038, 'calcitriol'), ('CL_0000233', 'platelet', 2071, 'Platelet'), ('GO_0030168', 'platelet activation', 2071, 'Platelet-activating'), ('GO_0007608', 'sensory perception of smell', 2127, '... death'), ('CL_0000233', 'platelet', 2149, 'platelet'), ('GO_0030168', 'platelet activation', 2149, 'platelet-activating'), ('CL_0000235', 'macrophage', 2184, 'macrophages'), ('PR_000008689', 'homeobox protein Hox-A13', 2200, 'HOXA10'), ('PR_000008469', 'holocytochrome c-type synthase', 2208, 'Homeobox A10'), ('GO_0008219', 'cell death', 2221, 'Cell life ... death'), ('UBERON_0000104', 'life cycle', 2226, 'life'), ('GO_0007601', 'visual perception', 2241, 'Embryo'), ('UBERON_0000922', 'embryo', 2241, 'Embryo'), ('GO_0007446', 'imaginal disc growth', 2248, 'implantationDecidual'), ('PR_000021995', 'dual specificity mitogen-activated protein kinase kinase 4 phosphorylated form', 2279, 'OsteopontinBone'), ('CHEBI_46662', 'mineral', 2299, 'mineral'), ('GO_0008152', 'metabolic process', 2307, 'metabolism'), ('UBERON_0000922', 'embryo', 2318, 'Embryo'), ('GO_0007446', 'imaginal disc growth', 2325, 'implantationDecidual'), ('CL_0000573', 'retinal cone cell', 2346, 'cells'), ('PR_000000035', 'BMP receptor type-1A', 2356, 'HBD2Immune'), ('PR_000000035', 'BMP receptor type-1A', 2412, 'HBD3Immune'), ('CHEBI_27300', 'vitamin D', 2590, 'vitamin D'), ('UBERON_0005063', 'left ventricular compact myocardium', 2624, 'Endocrine'), ('CHEBI_28384', 'vitamin K', 2648, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 2648, 'Vitamin'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 2678, '25OHD'), ('UBERON_0005063', 'left ventricular compact myocardium', 2847, 'Endocrine')]"
S91-PMC4377879	PMC4377879	3/2015	S91-PMC4377879	['there was an earlier RECOMMENDATION by the fao (food and agricultural organization)/who of a 40% increase in the Vitamin B-12 dietary allowance to meet foetal demands and increased Metabolic needs [21].']	[('FUTURE_WORK', 21)]	1	[('CHEBI_27300', 'vitamin D', 113, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 113, 'vitamin B-12'), ('GO_0008152', 'metabolic process', 181, 'metabolic')]
S31-PMC4404267	PMC4404267	4/2015	S31-PMC4404267	['in addition, certain physiological conditions (Vitamin D depletion, hypokalaemia, Metabolic acidosis) and Pharmacological Drugs (Nsaids, Glucocorticoids) are KNOWN to down-regulate Slc13A1 mrna and protein Expression [27].']	[('INCOMPLETE_EVIDENCE', 158)]	1	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0008152', 'metabolic process', 82, 'metabolic'), ('CHEBI_33832', 'organic cyclic compound', 106, 'pharmacological drugs'), ('CHEBI_13389', 'NAD', 129, 'NSAIDS'), ('CHEBI_36597', 'phthalazine', 137, 'glucocorticoids'), ('PR_000014939', 'urea transporter 2', 181, 'SLC13A1'), ('GO_0010467', 'gene expression', 206, 'expression')]
S31-PMC4417995	PMC4417995	4/2015	S31-PMC4417995	"[""Vitamin D and Immune Regulation\nthe extent of Vitamin D's biological actions goes further THAN Calcium Homeostasis and bone Metabolism.""]"	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 90)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0002326', 'B cell lineage commitment', 14, 'Immune Regulation'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0050817', 'coagulation', 95, 'calcium'), ('GO_0042592', 'homeostatic process', 103, 'homeostasis'), ('GO_0008152', 'metabolic process', 124, 'metabolism')]
S549-PMC4448820	PMC4448820	5/2015	S549-PMC4448820	['● a high infectious disease burden CAN lead to decreased appetite, decreased absorption, Liver or Kidney disease, and other FACTORS AFFECTING loss of Retinol Binding Protein (rbp), and depletion of body stores through excessive Metabolism and increased Excretion Of Vitamin A (325).']	[('INCOMPLETE_EVIDENCE', 35), ('SUPERFICIAL_RELATIONSHIP', 124), ('SUPERFICIAL_RELATIONSHIP', 132)]	3	[('UBERON_0002107', 'liver', 89, 'liver'), ('UBERON_0002113', 'kidney', 98, 'kidney'), ('CHEBI_26536', 'retinoic acid', 150, 'retinol'), ('PR_000014009', 'regulating synaptic membrane exocytosis protein 1', 150, 'retinol binding protein'), ('GO_0008152', 'metabolic process', 228, 'metabolism'), ('GO_0006881', 'extracellular sequestering of iron ion', 253, 'excretion of vitamin A'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin A')]
S48-PMC4499946	PMC4499946	7/2015	S48-PMC4499946	['clinical, biochemical, and microbiological Surveillance of enrolled mother-infant pairs will enable a range of secondary objectives to be addressed, including (1) estimation of the EFFECT of maternal Vitamin D supplementation on the incidence of acute Respiratory infections (aris) during early infancy; (2) exploration of the ROLES of specific hormones, Nutrients, environmental Contaminants, and inflammatory markers in the mediation or modification of the EFFECT of Vitamin D on fetal and infant growth, with particular emphasis on the ROLE of the Parathyroid hormone (pth) system; and (3) investigation of the ROLE of epigenetic modification of Genes involved in Perinatal Vitamin D Metabolism in infant stunting.']	[('SUPERFICIAL_RELATIONSHIP', 181), ('SUPERFICIAL_RELATIONSHIP', 327), ('SUPERFICIAL_RELATIONSHIP', 459), ('SUPERFICIAL_RELATIONSHIP', 539), ('SUPERFICIAL_RELATIONSHIP', 614)]	5	[('GO_0065007', 'biological regulation', 43, 'surveillance'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 252, 'respiratory'), ('CHEBI_33284', 'nutrient', 355, 'nutrients'), ('CHEBI_60688', 'EC 4.2.1.20 (tryptophan synthase) inhibitor', 380, 'contaminants'), ('CHEBI_27300', 'vitamin D', 469, 'vitamin D'), ('UBERON_0001132', 'parathyroid gland', 551, 'parathyroid'), ('SO_0000704', 'gene', 649, 'genes'), ('GO_0036268', 'swimming', 667, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 667, 'perinatal'), ('CHEBI_27300', 'vitamin D', 677, 'vitamin D'), ('GO_0008152', 'metabolic process', 687, 'metabolism')]
S296-PMC4499946	PMC4499946	7/2015	S296-PMC4499946	['the trial is primarily DESIGNED and powered TO EVALUATE the dose–response EFFECTS of Vitamin D on infant length, an outcome that is directly ALIGNED with the classical ROLE of Vitamin D in Mineral Metabolism and bone health BUT MAY also be interpreted as a SURROGATE marker for Organ (including Brain) Growth and Development.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 23), ('QUESTION_ANSWERED_BY_THIS_WORK', 44), ('SUPERFICIAL_RELATIONSHIP', 74), ('SUPERFICIAL_RELATIONSHIP', 141), ('SUPERFICIAL_RELATIONSHIP', 168), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 224), ('INCOMPLETE_EVIDENCE', 228), ('SUPERFICIAL_RELATIONSHIP', 257)]	8	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D'), ('CHEBI_46662', 'mineral', 189, 'mineral'), ('GO_0008152', 'metabolic process', 197, 'metabolism'), ('UBERON_0000062', 'organ', 278, 'organ'), ('GO_0007420', 'brain development', 295, 'brain ... growth ... development'), ('UBERON_0000955', 'brain', 295, 'brain')]
S20-PMC4516109	PMC4516109	5/2015	S20-PMC4516109	['clinical presentations include Abdominal pain, vomiting, lethargy, hallucinations, confusion, hypoglycemia, deafness, tinnitus, tachypnea, irritability, Metabolic acidosis, coma and death.15\nrisks of OTHER topical agents, such as Anthralin and Calcipotriol on Human studies are NOT KNOWN and THUS most authors CONTRAINDICATE these treatments.7,15calcipotriol is a by-product of Vitamin D3, OFTEN used in combination with topical Corticosteroids in order to increase their effectiveness and minimize irritation.12nevertheless, studies evidenced its systemic absorption in Humans after application on psoriasis plaques and the development of Vitamin D-induced toxicity after treatment with Calcipotriol TENDS to increase the risk of teratogenicity.12\nALTHOUGH the NUMBER OF cases is LIMITED, coal tar HAS BEEN ASSOCIATED with spontaneous Abortions and congenital disorders, and WAS CONSIDERED Teratogenic in Animal studies.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 200), ('FULL_UNKNOWN', 278), ('PROBABLE_UNDERSTANDING', 292), ('IMPORTANT_CONSIDERATION', 310), ('PROBABLE_UNDERSTANDING', 390), ('SUPERFICIAL_RELATIONSHIP', 701), ('ANOMALY_CURIOUS_FINDING', 749), ('INCOMPLETE_EVIDENCE', 762), ('INCOMPLETE_EVIDENCE', 781), ('INCOMPLETE_EVIDENCE', 799), ('SUPERFICIAL_RELATIONSHIP', 808), ('INCOMPLETE_EVIDENCE', 876)]	12	[('UBERON_0000916', 'abdomen', 31, 'abdominal'), ('GO_0008152', 'metabolic process', 153, 'metabolic'), ('CHEBI_37510', 'anthralin', 230, 'anthralin'), ('CHEBI_50749', 'calcipotriol', 244, 'calcipotriol'), ('NCBITaxon_9606', 'Homo sapiens', 260, 'human'), ('CHEBI_33279', 'vitamin D5', 378, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 378, 'vitamin D3'), ('CHEBI_50850', 'etabonate ester', 429, 'corticosteroids'), ('NCBITaxon_9606', 'Homo sapiens', 571, 'humans'), ('CHEBI_27300', 'vitamin D', 640, 'vitamin D'), ('CHEBI_50749', 'calcipotriol', 688, 'calcipotriol'), ('GO_0006915', 'apoptotic process', 836, 'abortions'), ('CHEBI_50905', 'teratogenic agent', 891, 'teratogenic'), ('NCBITaxon_33208', 'Metazoa', 906, 'animal')]
S13-PMC4516377	PMC4516377	6/2015	S13-PMC4516377	['the deficiency of Micronutrients, such as Calcium and Vitamin D, is common in many countries, REGARDLESS OF the nutritional status; HOWEVER, its magnitude is greater in children with excess weight.2,5-7in this context, CONCERNS about the ASSOCIATION between Calcium intake and Serum Vitamin D and Metabolic diseases in children has gained prominence in the scientific world for at least 30 years,8and SEVERAL STUDIES HAVE ATTEMPTED to clarify the several QUESTIONS about the subject,6,9,10as the combination of low Serum 25-Hydroxyvitamin D (25 [Oh] D) and INADEQUATE Calcium Intake HAS BEEN ASSOCIATED with Cardiovascular risk factors such as hypertension, obesity, Metabolic syndrome (ms) and type 2 diabetes mellitus.2,4,5,8that is, the combined deficiency of both Nutrients DESERVE special CONSIDERATION in children.4\nHOWEVER, the RECOMMENDATIONS of Calcium and Vitamin D intake have NOT been PROPOSED for the PREVENTION of noncommunicable chronic diseases, AS the STUDIES are STILL SCARCE, INCONSISTENT and SOMETIMES of poor quality.11ALTHOUGH Vitamin D insufficiency and low Calcium intake are commonly REPORTED, LITTLE IS KNOWN about the EFFECT of these Micronutrients in the prevention and treatment of diseases such as obesity.']	[('INCOMPLETE_EVIDENCE', 94), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 132), ('PROBLEM_COMPLICATION', 219), ('SUPERFICIAL_RELATIONSHIP', 238), ('INCOMPLETE_EVIDENCE', 401), ('IMPORTANT_CONSIDERATION', 417), ('DIFFICULT_TASK', 422), ('INCOMPLETE_EVIDENCE', 422), ('EXPLICIT_QUESTION', 455), ('IMPORTANT_CONSIDERATION', 557), ('INCOMPLETE_EVIDENCE', 583), ('SUPERFICIAL_RELATIONSHIP', 592), ('IMPORTANT_CONSIDERATION', 778), ('FUTURE_WORK', 794), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 822), ('FUTURE_WORK', 835), ('ANOMALY_CURIOUS_FINDING', 888), ('INCOMPLETE_EVIDENCE', 897), ('SUPERFICIAL_RELATIONSHIP', 914), ('PROBABLE_UNDERSTANDING', 962), ('INCOMPLETE_EVIDENCE', 969), ('IMPORTANT_CONSIDERATION', 981), ('INCOMPLETE_EVIDENCE', 987), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 995), ('INCOMPLETE_EVIDENCE', 1012), ('ANOMALY_CURIOUS_FINDING', 1038), ('INCOMPLETE_EVIDENCE', 1109), ('FULL_UNKNOWN', 1119), ('SUPERFICIAL_RELATIONSHIP', 1145)]	29	[('CHEBI_33839', 'macromolecule', 18, 'micronutrients'), ('CHEBI_22313', 'alkaline earth metal atom', 42, 'calcium'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 258, 'calcium'), ('UBERON_0001977', 'blood serum', 277, 'serum'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D'), ('GO_0008152', 'metabolic process', 297, 'metabolic'), ('UBERON_0001977', 'blood serum', 515, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 521, '25-hydroxyvitamin D'), ('CHEBI_15643', '(6R)-6-(L-erythro-1,2-dihydroxypropyl)-7,8-dihydro-6H-pterin', 542, '25 [OH] D'), ('CHEBI_22313', 'alkaline earth metal atom', 568, 'calcium'), ('GO_0007631', 'feeding behavior', 576, 'intake'), ('UBERON_0004535', 'cardiovascular system', 608, 'cardiovascular'), ('GO_0008152', 'metabolic process', 667, 'metabolic'), ('CHEBI_33284', 'nutrient', 768, 'nutrients'), ('CHEBI_22313', 'alkaline earth metal atom', 854, 'calcium'), ('CHEBI_27300', 'vitamin D', 866, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1049, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 1081, 'calcium'), ('CHEBI_33839', 'macromolecule', 1161, 'micronutrients')]
S52-PMC4516377	PMC4516377	6/2015	S52-PMC4516377	['moreover, Calcitriol inhibit s the Expression of Uncoupling Protein-2 (INVOLVED in the Regulation Of Metabolism, diet-induced Thermogenesis and body weight Control) through the classic Nuclear Vitamin D receptors in Adipocytes, thereby increasing energy efficiency.24,25additionally, the Regulation by Calcitriol of the Uncoupling Protein-2 and the levels of Intracellular calcium SEEMS to have an EFFECT on energy Metabolism by AFFECTING Adipocyte Apoptosis.24\n\n\ncaption (fig): figure 2.']	[('SUPERFICIAL_RELATIONSHIP', 71), ('ANOMALY_CURIOUS_FINDING', 381), ('SUPERFICIAL_RELATIONSHIP', 398), ('SUPERFICIAL_RELATIONSHIP', 429)]	4	[('CHEBI_17823', 'calcitriol', 10, 'calcitriol'), ('GO_0010467', 'gene expression', 35, 'expression'), ('PR_000017016', 'E3 ubiquitin-protein ligase UBR5', 49, 'uncoupling protein-2'), ('GO_0009894', 'regulation of catabolic process', 87, 'regulation of metabolism'), ('GO_0031649', 'heat generation', 126, 'thermogenesis'), ('GO_0065007', 'biological regulation', 156, 'control'), ('GO_0005634', 'nucleus', 185, 'nuclear'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin D'), ('CL_0000136', 'fat cell', 216, 'adipocytes'), ('GO_0065007', 'biological regulation', 288, 'regulation'), ('CHEBI_17823', 'calcitriol', 302, 'calcitriol'), ('PR_000017016', 'E3 ubiquitin-protein ligase UBR5', 320, 'uncoupling protein-2'), ('GO_0005622', 'intracellular anatomical structure', 359, 'intracellular'), ('GO_0008152', 'metabolic process', 415, 'metabolism'), ('CL_0000136', 'fat cell', 439, 'adipocyte'), ('GO_0006915', 'apoptotic process', 449, 'apoptosis')]
S65-PMC4516377	PMC4516377	6/2015	S65-PMC4516377	['THUS, the active transport becomes the main mechanism of calcium absorption when its Ingestion is low.34\nit can be OBSERVED that many of the mechanisms that explain adiposity and its ASSOCIATION with the assessed Micronutrients DEMONSTRATE the close ASSOCIATION between Calcium and the Vitamin D present in the Metabolic events of Adipogenesis, and the fact that the presence or absence of one of them CAN bring damage not only to bone, but health as a whole.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 115), ('SUPERFICIAL_RELATIONSHIP', 183), ('QUESTION_ANSWERED_BY_THIS_WORK', 228), ('SUPERFICIAL_RELATIONSHIP', 250), ('INCOMPLETE_EVIDENCE', 402)]	6	[('GO_0007631', 'feeding behavior', 85, 'ingestion'), ('CHEBI_33839', 'macromolecule', 213, 'micronutrients'), ('CHEBI_22313', 'alkaline earth metal atom', 270, 'calcium'), ('CHEBI_27300', 'vitamin D', 286, 'vitamin D'), ('GO_0008152', 'metabolic process', 311, 'metabolic'), ('GO_0060612', 'adipose tissue development', 331, 'adipogenesis')]
S116-PMC4632418	PMC4632418	10/2015	S116-PMC4632418	['there are MAJOR causes behind Vitamin D deficiency during Pregnancy, such as INADEQUATE exposure to sunlight, low Vitamin D intake and more REQUIREMENTS for Vitamin D. Vitamin D supplementation during Pregnancy has beneficial EFFECTS on glycaemia, Insulin sensitivity [45], Insulin resistance [46] and Metabolic profiles [47].']	[('IMPORTANT_CONSIDERATION', 10), ('IMPORTANT_CONSIDERATION', 77), ('IMPORTANT_CONSIDERATION', 140), ('SUPERFICIAL_RELATIONSHIP', 226)]	4	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 168, 'Vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 176, 'D'), ('GO_0007565', 'female pregnancy', 201, 'pregnancy'), ('PR_000045358', 'insulin family protein', 248, 'insulin'), ('PR_000045358', 'insulin family protein', 274, 'insulin'), ('GO_0008152', 'metabolic process', 302, 'metabolic')]
S7-PMC4670104	PMC4670104	12/2015	S7-PMC4670104	['negatively associated proteins exhibited distinct differences in abundance between secretory Hepatic proteins involved in transporting or binding Lipids, Micronutrients (Vitamin A and Calcium), growth factors and sex hormones, and proteins of largely extra-Hepatic origin INVOLVED in the Formation and Metabolic Regulation Of Extracellular Matrix.']	[('SUPERFICIAL_RELATIONSHIP', 272)]	1	[('UBERON_0002107', 'liver', 93, 'hepatic'), ('CHEBI_18059', 'lipid', 146, 'lipids'), ('CHEBI_33839', 'macromolecule', 154, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin A'), ('CHEBI_22313', 'alkaline earth metal atom', 184, 'calcium'), ('UBERON_0002107', 'liver', 257, 'hepatic'), ('GO_0007631', 'feeding behavior', 288, 'formation ...'), ('GO_0008152', 'metabolic process', 302, 'metabolic'), ('GO_0010524', 'positive regulation of calcium ion transport into cytosol', 312, 'regulation of ... matrix'), ('GO_0031012', 'extracellular matrix', 326, 'extracellular matrix')]
S1-PMC4673623	PMC4673623	11/2015	S1-PMC4673623	['Folate, Choline, betaine and Vitamin B-12) during Pregnancy is ESSENTIAL for normal maternal and fetal Methionine Metabolism, and is CRITICAL for IMPORTANT Metabolic processes including those INVOLVED in developmental programming.']	[('IMPORTANT_CONSIDERATION', 63), ('IMPORTANT_CONSIDERATION', 133), ('IMPORTANT_CONSIDERATION', 146), ('SUPERFICIAL_RELATIONSHIP', 192)]	4	[('CHEBI_30863', '5-azaorotic acid', 0, 'folate'), ('CHEBI_15354', 'choline', 8, 'choline'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 29, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('GO_0006555', 'methionine metabolic process', 103, 'methionine metabolism'), ('GO_0008152', 'metabolic process', 156, 'metabolic')]
S15-PMC4673623	PMC4673623	11/2015	S15-PMC4673623	['Folate, Vitamin B-12, Choline, and betaine) to several IMPORTANT Metabolic Processes (kalhan and marczewski2012) including those INVOLVED in developmental programming.']	[('IMPORTANT_CONSIDERATION', 55), ('SUPERFICIAL_RELATIONSHIP', 129)]	2	[('CHEBI_30863', '5-azaorotic acid', 0, 'folate'), ('CHEBI_27300', 'vitamin D', 8, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 8, 'vitamin B-12'), ('CHEBI_15354', 'choline', 22, 'choline'), ('GO_0008152', 'metabolic process', 65, 'metabolic processes')]
S113-PMC4673623	PMC4673623	11/2015	S113-PMC4673623	['a POSSIBLE EXPLANATION for the rise in Folate is impaired Vitamin B-12 dependent methionine synthase activity, with subsequent cellular accumulation of 5-Methyl-Thf (i.e., Metabolic trapping of Folate; methyl trap) (caudill et\xa0al.2012).']	[('INCOMPLETE_EVIDENCE', 2), ('PROBABLE_UNDERSTANDING', 11)]	2	[('CHEBI_30863', '5-azaorotic acid', 39, 'folate'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 58, 'vitamin B-12'), ('CHEBI_44700', 'L-ornithyl group', 152, '5-methyl'), ('CHEBI_17038', 'fecosterol', 161, 'THF'), ('GO_0008152', 'metabolic process', 172, 'metabolic'), ('CHEBI_30863', '5-azaorotic acid', 194, 'folate')]
S116-PMC4673623	PMC4673623	11/2015	S116-PMC4673623	['the Vitamin B-12 deficiency that led to the Metabolic trapping of Folate in the hf-hed group MAY BE RELATED to the caloric/Lipid load (mccurdy2009) and increased use of Vitamin B-12 as a lipotrope.']	[('INCOMPLETE_EVIDENCE', 93), ('SUPERFICIAL_RELATIONSHIP', 100)]	2	[('CHEBI_27300', 'vitamin D', 4, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 4, 'vitamin B-12'), ('GO_0008152', 'metabolic process', 44, 'metabolic'), ('CHEBI_30863', '5-azaorotic acid', 66, 'folate'), ('CHEBI_18059', 'lipid', 123, 'lipid'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 169, 'vitamin B-12')]
S65-PMC4684854	PMC4684854	12/2015	S65-PMC4684854	['dosing of Supplements, body weight, levels of various Toxicants, and individual Metabolism can all be FACTORS in consequent Vitamin D indices after supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 102)]	1	[('CHEBI_33341', 'titanium atom', 10, 'supplements'), ('CHEBI_35704', 'N(2)-acetyl-L-lysine', 54, 'toxicants'), ('GO_0008152', 'metabolic process', 80, 'metabolism'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]
S16-PMC4689556	PMC4689556	12/2015	S16-PMC4689556	['SEVERAL STUDIES have LINKED low Vitamin D status to a number of resource intensive childhood health PROBLEMS including allergy and infection [2–7], in addition to the WELL-ESTABLISHED EFFECTS on bone Metabolism.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 21), ('IMPORTANT_CONSIDERATION', 100), ('PROBABLE_UNDERSTANDING', 167), ('SUPERFICIAL_RELATIONSHIP', 184)]	5	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0008152', 'metabolic process', 200, 'metabolism')]
S116-PMC4690051	PMC4690051	12/2015	S116-PMC4690051	['the presence of 1α-hydroxylase activity within numerous Brain Regions SUGGESTS that Brain Tissue can locally produce Metabolically active Vitamin D, further IMPLICATING a ROLE for Vitamin D in Brain Development.']	[('INCOMPLETE_EVIDENCE', 70), ('PROBABLE_UNDERSTANDING', 157), ('SUPERFICIAL_RELATIONSHIP', 171)]	3	[('UBERON_0002616', 'regional part of brain', 56, 'brain regions'), ('UBERON_0000955', 'brain', 84, 'brain'), ('UBERON_0000479', 'tissue', 90, 'tissue'), ('GO_0008152', 'metabolic process', 117, 'metabolically'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D'), ('GO_0007420', 'brain development', 193, 'brain development'), ('UBERON_0000955', 'brain', 193, 'brain')]
S88-PMC4785305	PMC4785305	3/2016	S88-PMC4785305	['current Medications LIKELY to interfere with Vitamin D Metabolism (enzyme inducing Anticonvulsants, antituberculosis).']	[('PROBABLE_UNDERSTANDING', 20)]	1	[('CHEBI_25441', 'mycothiols', 8, 'medications'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007601', 'visual perception', 45, 'vitamin D'), ('GO_0008152', 'metabolic process', 55, 'metabolism'), ('CHEBI_37540', 'arabinarate(2-)', 83, 'anticonvulsants')]
S135-PMC4910734	PMC4910734	6/2015	S135-PMC4910734	['MANY of the Micronutrients STUDIES HAVE BEEN BASED ON Plasma and Urinary clinical results, which SUGGEST the elevation of Lipid Peroxide-generated Aldehydes (Hne, mda)84–86as well as deficiencies in antioxidants, such as Vitamin E, Sulfur-containing Compounds, such as cysteine, methionine, and Gsh,119carnitine,120biotin,121and ( n -3) pufas.122given the depressed levels of Sulfur-containing Compounds in asd Individuals, it is NOT SURPRISING that these children are more sensitive than neurotypicals to the exposure of mercury and other heavy metals.78the antioxidant supplements, which SHOW symptom improvements include, but are not limited to Ubiquinol,123nac,124carnosine, and Vitamin C.125other Micronutrients, including b1,126B6-Mg2+,127Folate, Vitamin E, Retinol, and Zn2+, HAVE BEEN selected for a variety of reasons RELATING to the INVOLVEMENT in abnormal Metabolic pathways IMPLICATED in asd,1even THOUGH the clinical assays do not always show a deficiency in asd Individuals compared to neurotypical controls.119with all of the single Micronutrient STUDIES, there are CONFLICTING results regarding efficacy.119there are a FEW STUDIES, which utilize broad-spectrum Micronutrient supplementation and report improvements in clinical BIOMARKERS and/or various autism-rating scales.76,121,128the broad-spectrum Micronutrient STUDIES are very PROMISING BECAUSE all DEMONSTRATE a significant CORRELATION between nutritional deficiencies and severity of autistic symptoms.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 35), ('INCOMPLETE_EVIDENCE', 45), ('INCOMPLETE_EVIDENCE', 97), ('PROBABLE_UNDERSTANDING', 430), ('ANOMALY_CURIOUS_FINDING', 434), ('INCOMPLETE_EVIDENCE', 590), ('INCOMPLETE_EVIDENCE', 783), ('SUPERFICIAL_RELATIONSHIP', 827), ('SUPERFICIAL_RELATIONSHIP', 843), ('SUPERFICIAL_RELATIONSHIP', 886), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 910), ('ANOMALY_CURIOUS_FINDING', 910), ('INCOMPLETE_EVIDENCE', 1062), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1081), ('INCOMPLETE_EVIDENCE', 1135), ('SUPERFICIAL_RELATIONSHIP', 1243), ('INCOMPLETE_EVIDENCE', 1333), ('PROBABLE_UNDERSTANDING', 1350), ('PROBABLE_UNDERSTANDING', 1360), ('INCOMPLETE_EVIDENCE', 1372), ('SUPERFICIAL_RELATIONSHIP', 1398)]	23	[('CHEBI_33839', 'macromolecule', 12, 'micronutrients'), ('UBERON_0001969', 'blood plasma', 54, 'plasma'), ('UBERON_0001088', 'urine', 65, 'urinary'), ('CHEBI_48107', 'nitric acid', 122, 'lipid peroxide'), ('CHEBI_17478', 'aldehyde', 147, 'aldehydes'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 158, 'HNE'), ('CHEBI_27300', 'vitamin D', 221, 'vitamin E'), ('CHEBI_36933', 'oxygen-19 atom', 232, 'sulfur'), ('CHEBI_36357', 'polyatomic entity', 250, 'compounds'), ('CHEBI_16856', 'glutathione', 295, 'GSH'), ('CHEBI_36933', 'oxygen-19 atom', 376, 'sulfur'), ('CHEBI_36357', 'polyatomic entity', 394, 'compounds'), ('NCBITaxon_1', 'root', 411, 'individuals'), ('CHEBI_17976', 'ubiquinol', 648, 'ubiquinol'), ('CHEBI_27300', 'vitamin D', 683, 'vitamin C'), ('CHEBI_33839', 'macromolecule', 702, 'micronutrients'), ('CHEBI_73173', '2,4-DB', 731, '126B6'), ('CHEBI_6636', 'magnesium dichloride', 737, 'Mg2+,'), ('CHEBI_75275', 'tetradecyl sulfonic acid', 742, '127folate'), ('CHEBI_27300', 'vitamin D', 753, 'vitamin E'), ('CHEBI_26536', 'retinoic acid', 764, 'retinol'), ('CHEBI_29105', 'zinc(2+)', 777, 'Zn2+,'), ('GO_0008152', 'metabolic process', 867, 'metabolic'), ('NCBITaxon_1', 'root', 976, 'individuals'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 1048, 'micronutrient'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 1177, 'micronutrient'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 1319, 'micronutrient')]
S126-PMC4934634	PMC4934634	11/2015	S126-PMC4934634	[', INVESTIGATED the EFFECTS of Vitamin D co-supplemented with Calcium on Metabolic parameters in women diagnosed with Gestational diabetes starting in their 24th–28th week of Gestation.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 2), ('SUPERFICIAL_RELATIONSHIP', 19)]	2	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 61, 'calcium'), ('GO_0008152', 'metabolic process', 72, 'metabolic'), ('GO_0007565', 'female pregnancy', 117, 'gestational'), ('GO_0007565', 'female pregnancy', 174, 'gestation')]
S132-PMC4934634	PMC4934634	11/2015	S132-PMC4934634	['WHILE Vitamin D supplementation to women with Gestational diabetes improved Metabolic parameters, what IS NEEDED are clinical trials investigating the extent to WHICH Vitamin D supplementation decreases adverse Perinatal outcomes ASSOCIATED with Gestational diabetes including macrosomia, Respiratory distress, and Postnatal hypoglycemia.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 103), ('EXPLICIT_QUESTION', 161), ('SUPERFICIAL_RELATIONSHIP', 230)]	4	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('GO_0007565', 'female pregnancy', 46, 'gestational'), ('GO_0008152', 'metabolic process', 76, 'metabolic'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D'), ('GO_0036268', 'swimming', 211, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 211, 'perinatal'), ('GO_0007565', 'female pregnancy', 246, 'gestational'), ('UBERON_0001004', 'respiratory system', 289, 'respiratory'), ('GO_0007567', 'parturition', 315, 'postnatal')]
S94-PMC4944244	PMC4944244	7/2016	S94-PMC4944244	['this high prevalence of hypovitaminosis D was DUE TO age, Abdominal obesity and Metabolic syndrome AFFECTING Vitamin D levels.']	[('PROBABLE_UNDERSTANDING', 46), ('SUPERFICIAL_RELATIONSHIP', 99)]	2	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 40, 'D'), ('UBERON_0000916', 'abdomen', 58, 'abdominal'), ('GO_0008152', 'metabolic process', 80, 'metabolic'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D')]
S90-PMC4969253	PMC4969253	8/2016	S90-PMC4969253	['circulating levels of Vitamin A (Retinol), Retinyl Esters, or ra do NOT NECESSARILY REFLECT the Retinoid status of target cells, SINCE activation of ra signaling depends on a COMPLEX interplay of the components of this pathway, including the presence of ra-synthesizing enzymes, ra receptors (rar, rxr), co-activators/co-repressors, and ra-Metabolizing enzymes.']	[('INCOMPLETE_EVIDENCE', 68), ('SUPERFICIAL_RELATIONSHIP', 84), ('PROBABLE_UNDERSTANDING', 129), ('PROBLEM_COMPLICATION', 129), ('DIFFICULT_TASK', 175)]	5	[('CHEBI_27300', 'vitamin D', 22, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 33, 'retinol'), ('CHEBI_26523', 'reactive oxygen species', 43, 'retinyl esters'), ('CHEBI_26537', 'retinoid', 96, 'retinoid'), ('GO_0008152', 'metabolic process', 340, 'metabolizing')]
S82-PMC4976416	PMC4976416	7/2016	S82-PMC4976416	['Vitamin E being a fat-soluble Vitamin, administration of a dose higher than daily REQUIREMENT results in accumulation inside the body, resulting in hypervitaminosis e. healthy Adults taking Vitamin E daily at a dose of 100 mg for more than 1 year are LIKELY to get hypervitaminosis E, manifesting as reduced Platelet Aggregation and interference with Vitamin K Metabolism resulting in bleeding tendencies.']	[('IMPORTANT_CONSIDERATION', 82), ('PROBABLE_UNDERSTANDING', 251)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 0, 'Vitamin E'), ('CHEBI_33229', 'vitamin (role)', 30, 'vitamin'), ('UBERON_0007023', 'adult organism', 176, 'adults'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin E'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 282, 'E'), ('CL_0000233', 'platelet', 308, 'platelet'), ('GO_0070527', 'platelet aggregation', 308, 'platelet aggregation'), ('CHEBI_27300', 'vitamin D', 351, 'vitamin K'), ('GO_0007601', 'visual perception', 351, 'vitamin K'), ('GO_0008152', 'metabolic process', 361, 'metabolism')]
S69-PMC5014971	PMC5014971	8/2016	S69-PMC5014971	['respondents were CONCERNED about Vitamin D deficiency and osteoporosis (91.1%) and bone fractures (88.1%), but less CONCERNED about other POSSIBLE sequelae of Vitamin D deficiency such as a weakened Immune System (32.7%), Colon cancer (27.7%), Cardiovascular disease (23.8%), impaired glucose Metabolism (22.8%), vulnerability to preeclampsia (22.8%), increased risk of small-for-Gestational-age infant (21.8%), vulnerability to Preterm Labor (19.8%), Breast cancer (14.9%), hypertension (12.9%), and infertility (10.9%).']	[('IMPORTANT_CONSIDERATION', 17), ('IMPORTANT_CONSIDERATION', 116), ('INCOMPLETE_EVIDENCE', 138)]	3	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D'), ('UBERON_0002405', 'immune system', 199, 'immune system'), ('UBERON_0001155', 'colon', 222, 'colon'), ('UBERON_0004535', 'cardiovascular system', 244, 'cardiovascular'), ('GO_0008152', 'metabolic process', 293, 'metabolism'), ('GO_0007565', 'female pregnancy', 380, 'gestational'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 429, 'preterm labor'), ('UBERON_0000310', 'breast', 452, 'breast')]
S102-PMC5014971	PMC5014971	8/2016	S102-PMC5014971	['in SUPPORT of the endocrine society RECOMMENDATIONS, SOME researchers POINT to the LIKELY higher circulating levels of 25-Oh-D in our ancestors that relied PRIMARILY on Photosynthetic Production Of Vitamin D, arguing that our Vitamin D Metabolism is adapted to high endogenous production [17,18].']	[('INCOMPLETE_EVIDENCE', 3), ('FUTURE_WORK', 36), ('INCOMPLETE_EVIDENCE', 53), ('INCOMPLETE_EVIDENCE', 70), ('PROBABLE_UNDERSTANDING', 83), ('PROBABLE_UNDERSTANDING', 156)]	6	[('CHEBI_46744', 'DDT-2,3-dihydrodiol', 119, '25-OH-D'), ('GO_0010264', 'myo-inositol hexakisphosphate biosynthetic process', 169, 'photosynthetic'), ('GO_0018240', 'protein S-linked glycosylation via cysteine', 184, 'production of vitamin D'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('GO_0007601', 'visual perception', 226, 'vitamin D'), ('GO_0008152', 'metabolic process', 236, 'metabolism')]
S105-PMC5014971	PMC5014971	8/2016	S105-PMC5014971	['there is also a direct ASSOCIATION between circulating 25-Oh-D and 1,25-Oh2-D, which is not the case outside of Pregnancy, SUGGESTING both higher substrate (25-Oh-D) turnover and a greater EFFECT of 25-Oh-D levels on Vitamin D actions on physiology and Metabolism [2].']	[('SUPERFICIAL_RELATIONSHIP', 23), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 189)]	3	[('CHEBI_46744', 'DDT-2,3-dihydrodiol', 55, '25-OH-D'), ('CHEBI_78731', '9(R)-HPETE', 69, '25-OH2-D'), ('GO_0007565', 'female pregnancy', 112, 'pregnancy'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 157, '25-OH-D'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 199, '25-OH-D'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin D'), ('GO_0008152', 'metabolic process', 253, 'metabolism')]
S71-PMC5024513	PMC5024513	9/2016	S71-PMC5024513	['caption (table-wrap): table 2\n\ncharacteristics of included studiesstudy informationparticipantssupplementsmeasurementqualitystudycountrystudy designstudy groupsnumberageinclusion criteriaexclusion criteriasupplement type and dosenumber with available dataestimated compliance: n (%)data collection method (s)time period(s)quality ratingbaker et.al (2009) [23]ukcross-sectional studyna50014–18singleton Pregnancy, age 14–18, Gestational age\u2009<\u2009=20\xa0weeksinability to provide informed consent, preeclampsia, Clotting disorders, hiv/aids, haemoglobinopathies, diabetes, Renal disease, hypertension, multiple Gestations, history of 3=\u2009>\u2009previous Miscarriagespreconception folic acid49834 (6.9)24\xa0h recall (multiple)third Trimester+Folic Acid in early pregnancy498220 (44.2)Iron in early pregnancy49839 (7.8)multivitamins in early pregnancy49819 (3.8)Folic Acid only in 3rd trimester2905 (1.7)Iron and Folic Acid in 3rd trimester29013 (4.5)Iron only in 3rd trimester29042 (14.5)multivitamins in 3rd trimester2907 (2.4)castillo-duran et.al (2001) [43]chilerctzinc supplemented24916.4 (mean)beginning Prenatal visits before 20\xa0weeks Gestation, aged <19 at estimated due dateadolescents whose background included chronic diseases, Drug abuse, mental retardation, illiteracy or Pregnancy due to incest or rape20\xa0mg Zinc Sulphate dailyintervention group - 249at least 50\xa0% compliance24\xa0h Recall (multiple)second and third Trimester+placebo25840\xa0mg Iron Sulphateall participants - 507chan et.al (2006) [24]usarctcontrol group, 2 intervention groups excluded from review*2315–17enrolled before 20\xa0weeks Gestationhypertension, diabetes, Renal or Liver disease, alcohol or tobacco use, using medicines effecting Ca Metabolismno additional supplements reportedfood diary (weighing not mentioned)second and third Trimester−/+chang et.al (2003) [37]usaretrospective chart reviewna91812–17self-reported racial group as african-american; singleton Pregnancybirth results not AVAILABLE DUE TO abortion, Miscarriage or transfer of care90\xa0mg Carbonyl Iron daily plus additional up to 120\xa0mg for those classified as anaemic918not reportednot reportedsecond and third Trimester+dawson et.al (2000) [35]usarctone-a-day without iron2016–20aged 16–20, less than 16\xa0weeks Gestation, no Iron supplementation for previous 30\xa0dayshypertension; diabetes; other medical problems; haemoglobin <11\xa0g/dl; haematocrit <30\xa0%vitamin a 5000\xa0iu, Vitamin D 400\xa0iu, Vitamin E 10\xa0mg, Vitamin C 60\xa0mg, Folic Acid 0.4\xa0mg, Thiamine 1.5\xa0mg, riboflavin 1.7\xa0mg, niacin 20\xa0mg, Pyridoxine 2\xa0mg, Vitamin B- 6\xa0mg, Pantothenic Acid 10\xa0mg20not reportedvenous Blood samplesecond and third Trimester and Delivery−/+one-a-day with iron2018\xa0mg iron, vitamin a 5000\xa0iu, Vitamin D 400\xa0iu, Vitamin E 10\xa0mg, Vitamin C 60\xa0mg, Folic Acid 0.4\xa0mg, Thiamine 1.5\xa0mg, riboflavin 1.7\xa0mg, Niacin 20\xa0mg, Pyridoxine 2\xa0mg, Vitamin B- 6\xa0mg, pantothenic Acid 10\xa0mg20derbyshire (2009) [39]ukcross-sectional studyna2015–19attending Antenatal classes or community clinicsincomplete diarynone reportedfood diary unweighedthird Trimester+gadowsky et.al (1995) [42]canadacross-sectional studyna5814–19not reportednot reportedfolic Acid mean 479\xa0μg/day5882\xa0%Venous Blood samplethird trimester+Elemental Iron mean 31.5\xa0mg/daycyanocobalamin (B12) mean 2.24\xa0μg/dgiddens et.al (2000) [27]usarct (subset from a larger study)na5913–18singleton Pregnancies, between 13 and 19\xa0weeks Gestationnot REPORTEDREPORTED that any contribution from Supplements was not included in analysisfood diary weighedmean over Pregnancy−/+ginde et.al (2010) [32]usasecondary analysis of cross sectional surveyna8413–19not reportednot reportedsome participants taking Vitamin D Supplementsnot reportednot reportedvenous Blood samplemean over Pregnancy+gutierrez et.al (1999) [28]usacross-sectional studyna4613–18self-identified ethnicity as mexican american, primigravida, 13–18 years of agehistory of Miscarriage or health problems, involved in competitive athletic performances or heavy exercise, planned to move away during study periodnone reported24\xa0h recall (single)second and third Trimester+iannotti et.al (2005) [36]usacross-sectional studyna8013–18self-reported racial group as african-american; singleton Pregnancynot reportednone reported10\xa0ml Venous Blood samplesecond and third trimesters+job et.al (1995) [41]australiacross-sectional studyna3513–19not reportednot reportednone REPORTED24\xa0h recallmean over Pregnancy+lee et.al (2013) [25]usacross-sectional studyna15613–18age 18 or under, carrying a single fetus, 12–30 weeks Gestation at recruitmentnot REPORTEDREPORTED that any CONTRIBUTION from Supplements was not included in analysis24\xa0h recall (multiple)<23\xa0weeks Gestation, 23–30 weeks Gestation and mean over Pregnancy+mcguire et.al.']	[('INCOMPLETE_EVIDENCE', 1954), ('PROBLEM_COMPLICATION', 1964), ('INCOMPLETE_EVIDENCE', 3401), ('INCOMPLETE_EVIDENCE', 4377), ('INCOMPLETE_EVIDENCE', 4553), ('SUPERFICIAL_RELATIONSHIP', 4579)]	6	[('GO_0007565', 'female pregnancy', 402, 'pregnancy'), ('GO_0007565', 'female pregnancy', 424, 'gestational'), ('GO_0050817', 'coagulation', 504, 'clotting'), ('UBERON_0002113', 'kidney', 565, 'renal'), ('GO_0007565', 'female pregnancy', 603, 'gestations'), ('GO_0050788', 'sequestering of mercury', 640, 'miscarriagesPreconception'), ('GO_0009294', 'DNA mediated transformation', 715, 'trimester'), ('CHEBI_30751', 'formic acid', 725, 'Folic acid'), ('CHEBI_24870', 'ion', 767, 'Iron'), ('CHEBI_30751', 'formic acid', 844, 'Folic acid'), ('CHEBI_24870', 'ion', 886, 'Iron'), ('CHEBI_30751', 'formic acid', 895, 'folic acid'), ('CHEBI_24870', 'ion', 933, 'Iron'), ('GO_0007565', 'female pregnancy', 1092, 'prenatal'), ('GO_0007565', 'female pregnancy', 1124, 'gestation'), ('CHEBI_23888', 'drug', 1221, 'drug'), ('GO_0007565', 'female pregnancy', 1267, 'pregnancy'), ('CHEBI_10127', 'zonisamide', 1304, 'Zinc sulphate'), ('GO_0060033', 'anatomical structure regression', 1376, 'recall'), ('GO_0009294', 'DNA mediated transformation', 1410, 'trimester'), ('CHEBI_83530', 'atenolol-desisopropyl', 1436, 'iron sulphateAll'), ('GO_0051866', 'general adaptation syndrome', 1589, 'gestationHypertension'), ('UBERON_0002113', 'kidney', 1622, 'renal'), ('UBERON_0002107', 'liver', 1631, 'liver'), ('CHEBI_32588', 'potassium chloride', 1696, 'Ca'), ('GO_0008152', 'metabolic process', 1699, 'metabolismNo'), ('GO_0009294', 'DNA mediated transformation', 1795, 'trimester'), ('GO_0007605', 'sensory perception of sound', 1927, 'pregnancyBirth'), ('GO_0046660', 'female sex differentiation', 1981, 'miscarriage'), ('CHEBI_30255', 'sulfidocarbonate(.1-)', 2018, 'carbonyl iron'), ('GO_0009294', 'DNA mediated transformation', 2142, 'trimester'), ('GO_0007565', 'female pregnancy', 2242, 'gestation'), ('CHEBI_24870', 'ion', 2256, 'iron'), ('CHEBI_27300', 'vitamin D', 2403, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 2421, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 2438, 'vitamin C'), ('CHEBI_30751', 'formic acid', 2455, 'folic acid'), ('CHEBI_26948', 'vitamin B1', 2474, 'thiamine'), ('CHEBI_16410', 'pyridoxamine', 2524, 'pyridoxine'), ('CHEBI_27300', 'vitamin D', 2541, 'vitamin B'), ('CHEBI_7916', 'pantothenic acid', 2558, 'pantothenic acid'), ('UBERON_0000178', 'blood', 2601, 'blood'), ('GO_0009294', 'DNA mediated transformation', 2630, 'trimester'), ('GO_0007567', 'parturition', 2644, 'delivery'), ('CHEBI_27300', 'vitamin D', 2707, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 2725, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 2742, 'vitamin C'), ('CHEBI_30751', 'formic acid', 2759, 'folic acid'), ('CHEBI_26948', 'vitamin B1', 2778, 'thiamine'), ('CHEBI_7542', 'neurotensin', 2814, 'niacin'), ('CHEBI_16410', 'pyridoxamine', 2828, 'pyridoxine'), ('CHEBI_27300', 'vitamin D', 2845, 'vitamin B'), ('CHEBI_37527', 'acid', 2874, 'acid'), ('GO_0007567', 'parturition', 2950, 'antenatal'), ('GO_0009294', 'DNA mediated transformation', 3043, 'trimester'), ('CHEBI_37527', 'acid', 3145, 'Acid'), ('UBERON_0001638', 'vein', 3171, 'Venous'), ('UBERON_0000178', 'blood', 3178, 'blood'), ('CHEBI_4779', 'emedastine', 3206, 'Elemental'), ('CHEBI_24870', 'ion', 3216, 'Iron'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 3253, 'B12'), ('GO_0007565', 'female pregnancy', 3351, 'pregnancies'), ('GO_0007565', 'female pregnancy', 3388, 'gestationNot'), ('CHEBI_33341', 'titanium atom', 3445, 'supplements'), ('GO_0007565', 'female pregnancy', 3513, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 3653, 'vitamin D'), ('CHEBI_46978', 'thiazinemonocarboxylic acid', 3663, 'supplementsNot'), ('UBERON_0000178', 'blood', 3705, 'blood'), ('GO_0007565', 'female pregnancy', 3727, 'pregnancy'), ('GO_0046660', 'female sex differentiation', 3887, 'miscarriage'), ('GO_0009294', 'DNA mediated transformation', 4074, 'trimester'), ('GO_0006915', 'apoptotic process', 4201, 'pregnancyNot'), ('UBERON_0001638', 'vein', 4241, 'Venous'), ('UBERON_0000178', 'blood', 4248, 'blood'), ('GO_0007565', 'female pregnancy', 4406, 'pregnancy'), ('GO_0007565', 'female pregnancy', 4525, 'gestation'), ('CHEBI_33341', 'titanium atom', 4597, 'supplements'), ('GO_0007565', 'female pregnancy', 4669, 'gestation'), ('GO_0007565', 'female pregnancy', 4692, 'gestation'), ('GO_0007565', 'female pregnancy', 4716, 'pregnancy')]
S17-PMC5051327	PMC5051327	9/2016	S17-PMC5051327	['introduction\nVitamin D is NECESSARY for optimal Skeletal function and deficiency is RELATED to rachitis.1\nit is, HOWEVER, IMPORTANT for bone Metabolism, as well as for optimal function of Striated and Smooth Muscle strength including Heart Muscle, and is RELATED to Postnatal muscle strength.2vitamin D supplementation has a positive IMPACT on muscle strength on Individuals with Vitamin D deficiency.134THE institute of medicine (iom), usa RECOMMENDS daily nutritional intake of Vitamin D of 600\u2005u, BUT OTHERS RECOMMEND higher doses.56a RECENT swedish STUDY SHOWED that the mean nutritional intake of Vitamin D was <200\u2005u/day.7ALTHOUGH Vitamin D is found in low amounts in the diet, mainly in oily fish and egg, the primary source of Vitamin D for Humans is skin conversion to Vitamin D from solar ultraviolet radiation.1pregnant women residing at high latitudes are AT RISK of Vitamin D deficiency BECAUSE of low solar intensity, especially during the winter months.18vitamin D deficiency is common in the nordic countries, ESPECIALLY among those not exposing themselves to the sun.8since fetal Vitamin D levels are directly RELATED to that of their mothers there is also a high LIKELIHOOD of fetal Vitamin D deficiency in our population.9\nBirth asphyxia is ASSOCIATED with Cardiovascular dysfunction, including low Ventricular output, lower left Ventricular Ejection fraction and increased troponin levels.1011congestive Heart failure MAY occur in severe cases of asphyxia.12intrauterine fetal distress is RELATED to an increase in Blood pressure, redistribution and a change in fetal Heart rate pattern.']	[('IMPORTANT_CONSIDERATION', 26), ('SUPERFICIAL_RELATIONSHIP', 84), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 113), ('IMPORTANT_CONSIDERATION', 122), ('SUPERFICIAL_RELATIONSHIP', 255), ('SUPERFICIAL_RELATIONSHIP', 334), ('INCOMPLETE_EVIDENCE', 401), ('FUTURE_WORK', 441), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 500), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 504), ('FUTURE_WORK', 511), ('INCOMPLETE_EVIDENCE', 538), ('INCOMPLETE_EVIDENCE', 559), ('ANOMALY_CURIOUS_FINDING', 627), ('IMPORTANT_CONSIDERATION', 868), ('PROBABLE_UNDERSTANDING', 900), ('ANOMALY_CURIOUS_FINDING', 1026), ('SUPERFICIAL_RELATIONSHIP', 1127), ('PROBABLE_UNDERSTANDING', 1181), ('SUPERFICIAL_RELATIONSHIP', 1260), ('INCOMPLETE_EVIDENCE', 1438), ('SUPERFICIAL_RELATIONSHIP', 1509)]	22	[('CHEBI_28384', 'vitamin K', 13, 'Vitamin D'), ('UBERON_0004288', 'skeleton', 48, 'skeletal'), ('GO_0008152', 'metabolic process', 141, 'metabolism'), ('UBERON_0002435', 'striatum', 188, 'striated'), ('UBERON_0001135', 'smooth muscle tissue', 201, 'smooth muscle'), ('UBERON_0001133', 'cardiac muscle tissue', 234, 'heart muscle'), ('GO_0007567', 'parturition', 266, 'postnatal'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 301, 'D'), ('NCBITaxon_1', 'root', 363, 'individuals'), ('CHEBI_27300', 'vitamin D', 380, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 480, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 602, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 637, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 735, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 749, 'humans'), ('CHEBI_27300', 'vitamin D', 778, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 879, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 978, 'D'), ('CHEBI_27300', 'vitamin D', 1097, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1201, 'vitamin D'), ('GO_0007567', 'parturition', 1242, 'Birth'), ('UBERON_0004535', 'cardiovascular system', 1276, 'cardiovascular'), ('UBERON_0002082', 'cardiac ventricle', 1318, 'ventricular'), ('UBERON_0002082', 'cardiac ventricle', 1349, 'ventricular'), ('UBERON_0000970', 'eye', 1361, 'ejection'), ('UBERON_0000948', 'heart', 1424, 'heart'), ('UBERON_0000178', 'blood', 1535, 'blood'), ('UBERON_0000948', 'heart', 1588, 'heart')]
S22-PMC5129897	PMC5129897	10/2016	S22-PMC5129897	['diseases included in THIS STUDY along with a brief overview of the mechanisms of Vitamin D for each disease and a listing of a few observational studies and clinical trials in support.diseasemechanismsobservational studiesclinical trialscancereffects on cells, Angiogenesis, and metastasis10breast and Colorectal cancer incidence11; survival12breast and all-cancer incidence13cvdeffects on Serum Cholesterol levels, Arterial stiffness, Insulin resistance, hyperglycemia, and increased incident Metabolic syndrome are POTENTIALLY PLAUSIBLE mediators8refs.14,15effect on cvd risk factors16dementiaregulation of Calcium Homeostasis, clearance of Amyloid-Β peptide, antioxidant and anti-inflammatory EFFECTS, and POSSIBLE protection against the neurodegenerative mechanisms ASSOCIATED with ad17incidence18\xa0dmimproves Insulin sensitivity and secretion, mainly via its anti-inflammatory properties19incidence20; meta-analysis21\xa0falls and fracturesreduces bone mass loss by reducing inflammation22; maintains cognition23; helps maintain muscle mass24ref.25ref.26mseffects on Regulatory T and B Cells27Ref.28\xa0respiratory infectionsinduction of Cathelicidin and defensins29; strengthens Adaptive and innate Immune System30Pneumonia31Influenza32,33; ari34\nad, alzheimer disease; ari, acute Respiratory Tract infection; cvd, Cardiovascular disease; dm, diabetes mellitus; ms, multiple sclerosis.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 21), ('INCOMPLETE_EVIDENCE', 517), ('INCOMPLETE_EVIDENCE', 529), ('SUPERFICIAL_RELATIONSHIP', 696), ('INCOMPLETE_EVIDENCE', 709), ('SUPERFICIAL_RELATIONSHIP', 770)]	6	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0001525', 'angiogenesis', 261, 'angiogenesis'), ('UBERON_0012652', 'colorectum', 302, 'colorectal'), ('UBERON_0001977', 'blood serum', 390, 'serum'), ('CHEBI_16113', 'cholesterol', 396, 'cholesterol'), ('UBERON_0001637', 'artery', 416, 'arterial'), ('PR_000045358', 'insulin family protein', 436, 'insulin'), ('GO_0008152', 'metabolic process', 494, 'metabolic'), ('GO_0055073', 'cadmium ion homeostasis', 609, 'calcium homeostasis'), ('PR_000004519', 'autism susceptibility gene 2 protein', 643, 'amyloid-β'), ('PR_000045358', 'insulin family protein', 813, 'insulin'), ('CL_0000815', 'regulatory T cell', 1068, 'regulatory T ...'), ('GO_0065007', 'biological regulation', 1068, 'regulatory'), ('CL_0000960', 'T3 B cell', 1085, 'B cells27Ref'), ('PR_000006009', 'alpha-catulin', 1136, 'cathelicidin'), ('GO_0051886', 'negative regulation of timing of anagen', 1178, 'adaptive ...'), ('UBERON_0003822', 'forelimb stylopod', 1198, 'immune system30Pneumonia31Influenza32'), ('UBERON_0000065', 'respiratory tract', 1280, 'respiratory tract'), ('UBERON_0004535', 'cardiovascular system', 1314, 'cardiovascular')]
S99-PMC5129897	PMC5129897	10/2016	S99-PMC5129897	['Vitamin D supplementation CAN improve osteoporosis and reduce fractures.26the classical ROLE of Vitamin D is to help with calcium absorption and Metabolism, leading to strong Bones.']	[('INCOMPLETE_EVIDENCE', 26), ('SUPERFICIAL_RELATIONSHIP', 88)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('GO_0008152', 'metabolic process', 145, 'metabolism'), ('UBERON_0001474', 'bone element', 175, 'bones')]
S22-PMC5155676	PMC5155676	12/2016	S22-PMC5155676	['during Pregnancy, maternal hemodilution is ACCOMPANIED by a number OF physiological changes to both Vitamin D Metabolism (15) and maternal body composition (16); such adaptations MIGHT lead to DIFFERENCES in the DETERMINANTS of response to Vitamin D supplementation between Pregnant and nonpregnant women.']	[('SUPERFICIAL_RELATIONSHIP', 43), ('ANOMALY_CURIOUS_FINDING', 67), ('INCOMPLETE_EVIDENCE', 179), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 193), ('SUPERFICIAL_RELATIONSHIP', 212)]	5	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007601', 'visual perception', 100, 'vitamin D'), ('GO_0008152', 'metabolic process', 110, 'metabolism'), ('CHEBI_27300', 'vitamin D', 240, 'vitamin D'), ('GO_0007565', 'female pregnancy', 274, 'pregnant')]
S64-PMC5410409	PMC5410409	4/2017	S64-PMC5410409	['the CONFLICTING results MAY reflect Genetic variability in the general population in the Metabolism and allergy preventive EFFECTS of Vitamin D supplementation in the child [67].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 123)]	3	[('SO_0000704', 'gene', 36, 'genetic'), ('GO_0008152', 'metabolic process', 89, 'metabolism'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]
S130-PMC5418719	PMC5418719	5/2017	S130-PMC5418719	['preterm infants with these diseases MAY more LIKELY to have low Vitamin D levels INVOLVED in impaired Vitamin D absorption or Metabolism during hospitalization.']	[('INCOMPLETE_EVIDENCE', 36), ('PROBABLE_UNDERSTANDING', 45), ('SUPERFICIAL_RELATIONSHIP', 81)]	3	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('GO_0008152', 'metabolic process', 126, 'metabolism')]
S0-PMC5685050	PMC5685050	10/2014	S0-PMC5685050	['vitamin D deficiency in thailand☆\nvitamin D deficiency has received INCREASED ATTENTION over the past several years since Vitamin D MAY play an IMPORTANT ROLE not ONLY in bone Metabolism but also in a variety of non-Skeletal diseases such as diabetes mellitus, Autoimmune diseases, infectious diseases, Cardiovascular diseases and cancer1,2,3.']	[('INCOMPLETE_EVIDENCE', 68), ('INCOMPLETE_EVIDENCE', 132), ('IMPORTANT_CONSIDERATION', 144), ('SUPERFICIAL_RELATIONSHIP', 154), ('INCOMPLETE_EVIDENCE', 163)]	5	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 8, 'D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 42, 'D'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('GO_0008152', 'metabolic process', 176, 'metabolism'), ('UBERON_0004288', 'skeleton', 216, 'skeletal'), ('UBERON_0001442', 'skeleton of manus', 261, 'autoimmune'), ('UBERON_0004535', 'cardiovascular system', 303, 'cardiovascular')]
S15-PMC5707701	PMC5707701	11/2017	S15-PMC5707701	['Vitamin A and Vitamin E are REQUIRED in many ESSENTIAL Metabolic functions for the growing infant [7,8].']	[('IMPORTANT_CONSIDERATION', 28), ('IMPORTANT_CONSIDERATION', 45)]	2	[('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin A'), ('CHEBI_27300', 'vitamin D', 14, 'vitamin E'), ('GO_0008152', 'metabolic process', 55, 'metabolic')]
S0-PMC5758521	PMC5758521	1/2018	S0-PMC5758521	['vitamin a and e nutritional status in RELATION to leptin, adiponectin, Igf-I and Igf-Ii in early Life - a Birth cohort study\n\nabstract\nthe Metabolic health EFFECTS of Vitamin A and E nutritional status in early Life are largely UNKNOWN.']	[('SUPERFICIAL_RELATIONSHIP', 38), ('SUPERFICIAL_RELATIONSHIP', 156), ('FULL_UNKNOWN', 228)]	3	[('PR_000008919', 'interferon alpha-6', 71, 'IGF-I'), ('PR_000002046', 'interferon regulatory factor 4', 81, 'IGF-II'), ('UBERON_0000104', 'life cycle', 97, 'Life'), ('GO_0007567', 'parturition', 106, 'Birth'), ('GO_0008152', 'metabolic process', 139, 'metabolic'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 181, 'E'), ('UBERON_0000104', 'life cycle', 211, 'life')]
S9-PMC5758521	PMC5758521	1/2018	S9-PMC5758521	['however, the Metabolic health EFFECTS of Vitamin A and E nutritional status in early Life remain largely UNKNOWN.']	[('SUPERFICIAL_RELATIONSHIP', 30), ('FULL_UNKNOWN', 105)]	2	[('GO_0008152', 'metabolic process', 13, 'metabolic'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 55, 'E'), ('UBERON_0000104', 'life cycle', 85, 'life')]
S19-PMC5758521	PMC5758521	1/2018	S19-PMC5758521	['taken TOGETHER, these OBSERVATIONS SUGGEST that Vitamins A and E MAY AFFECT Metabolic health.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 35), ('INCOMPLETE_EVIDENCE', 65), ('SUPERFICIAL_RELATIONSHIP', 69)]	5	[('CHEBI_27300', 'vitamin D', 48, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 63, 'E'), ('GO_0008152', 'metabolic process', 76, 'metabolic')]
S20-PMC5758521	PMC5758521	1/2018	S20-PMC5758521	['HOWEVER, there is a LACK OF DATA on WHETHER Vitamin A and E nutritional status MAY BE ASSOCIATED with Metabolic health BIOMARKERS in early Life in Humans.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 20), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 36), ('INCOMPLETE_EVIDENCE', 79), ('SUPERFICIAL_RELATIONSHIP', 86), ('SUPERFICIAL_RELATIONSHIP', 119)]	7	[('CHEBI_27300', 'vitamin D', 44, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 58, 'E'), ('GO_0008152', 'metabolic process', 102, 'metabolic'), ('UBERON_0000104', 'life cycle', 139, 'life'), ('NCBITaxon_9606', 'Homo sapiens', 147, 'humans')]
S21-PMC5758521	PMC5758521	1/2018	S21-PMC5758521	['to fill this IMPORTANT research data gap, we SOUGHT TO EVALUATE WHETHER Vitamin A and e nutritional status in neonates are ASSOCIATED with circulating concentrations of leptin, adiponectin, Igf-I and Igf-Ii which are IMPORTANT BIOMARKERS of fetal growth and Metabolic health15,16.']	[('IMPORTANT_CONSIDERATION', 13), ('QUESTION_ANSWERED_BY_THIS_WORK', 45), ('QUESTION_ANSWERED_BY_THIS_WORK', 52), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 64), ('SUPERFICIAL_RELATIONSHIP', 123), ('IMPORTANT_CONSIDERATION', 217), ('SUPERFICIAL_RELATIONSHIP', 227)]	7	[('CHEBI_27300', 'vitamin D', 72, 'vitamin A'), ('PR_000008919', 'interferon alpha-6', 190, 'IGF-I'), ('PR_000002046', 'interferon regulatory factor 4', 200, 'IGF-II'), ('GO_0008152', 'metabolic process', 258, 'metabolic')]
S119-PMC5758521	PMC5758521	1/2018	S119-PMC5758521	['these observations SUGGEST that Vitamin E and a nutritional status MAY matter for Metabolic health in early Life in Humans.']	[('INCOMPLETE_EVIDENCE', 19), ('INCOMPLETE_EVIDENCE', 67)]	2	[('CHEBI_27300', 'vitamin D', 32, 'vitamin E'), ('GO_0008152', 'metabolic process', 82, 'metabolic'), ('UBERON_0000104', 'life cycle', 108, 'life'), ('NCBITaxon_9606', 'Homo sapiens', 116, 'humans')]
S10-PMC5831579	PMC5831579	3/2018	S10-PMC5831579	['dietary Intake of fruits and vegetables, foods that require preparation, Nutrients from One-Carbon Metabolism, protein, iron, Calcium and Vitamin D were CORRELATED with the ‘seasoned vegetables and lean meats’.']	[('SUPERFICIAL_RELATIONSHIP', 153)]	1	[('GO_0007631', 'feeding behavior', 8, 'intake'), ('CHEBI_33284', 'nutrient', 73, 'nutrients'), ('GO_0007608', 'sensory perception of smell', 88, 'one-carbon'), ('GO_0008152', 'metabolic process', 99, 'metabolism'), ('CHEBI_22313', 'alkaline earth metal atom', 126, 'calcium'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D')]
S495-PMC5941617	PMC5941617	5/2018	S495-PMC5941617	['several rcts HAVE BEEN conducted to evaluate the efficacy of Vitamin D supplementation as a POTENTIAL therapy for each component of Metabolic syndrome.']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 92)]	2	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0008152', 'metabolic process', 132, 'metabolic')]
S515-PMC5941617	PMC5941617	5/2018	S515-PMC5941617	['MORE rcts ARE NEEDED to evaluate the INFLUENCE of Vitamin D supplementation on Controlling Metabolic syndrome.']	[('FUTURE_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 37)]	2	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('GO_0065007', 'biological regulation', 79, 'controlling'), ('GO_0008152', 'metabolic process', 91, 'metabolic')]
S648-PMC5941617	PMC5941617	5/2018	S648-PMC5941617	['Vitamin D status SHOULD BE monitored AT LEAST yearly in subjects that REQUIRE supplementation during the whole year BECAUSE AFFECTED from pathological conditions or receiving Drugs AFFECTING Vitamin D Metabolism (table\xa07).']	[('FUTURE_WORK', 17), ('IMPORTANT_CONSIDERATION', 17), ('PROBABLE_UNDERSTANDING', 37), ('IMPORTANT_CONSIDERATION', 70), ('PROBABLE_UNDERSTANDING', 116), ('SUPERFICIAL_RELATIONSHIP', 124), ('SUPERFICIAL_RELATIONSHIP', 181)]	7	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_23888', 'drug', 175, 'drugs'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D'), ('GO_0008152', 'metabolic process', 201, 'metabolism')]
S672-PMC5941617	PMC5941617	5/2018	S672-PMC5941617	['we SUGGEST the evaluation of Vitamin D status ONLY in patients affected by tuberculosis or hiv infection, AS they MAY BENEFIT from Vitamin D supplementation, in particular due to concomitant treatments that INFLUENCE Vitamin D Metabolism.']	[('FUTURE_WORK', 3), ('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 46), ('PROBABLE_UNDERSTANDING', 106), ('INCOMPLETE_EVIDENCE', 114), ('IMPORTANT_CONSIDERATION', 118), ('SUPERFICIAL_RELATIONSHIP', 207)]	7	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin D'), ('GO_0008152', 'metabolic process', 227, 'metabolism')]
S703-PMC5941617	PMC5941617	5/2018	S703-PMC5941617	['obesity and Metabolic syndrome\n\nepidemiological studies SHOWED that obese children and adolescents are at high RISK for Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 56), ('IMPORTANT_CONSIDERATION', 111)]	2	[('GO_0008152', 'metabolic process', 12, 'metabolic'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D')]
S705-PMC5941617	PMC5941617	5/2018	S705-PMC5941617	['it is UNCERTAIN IF Vitamin D deficiency MAY worsen Metabolic profile of obese children and adolescents.']	[('FULL_UNKNOWN', 6), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 16), ('INCOMPLETE_EVIDENCE', 40)]	3	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0008152', 'metabolic process', 51, 'metabolic')]
S14-PMC5952272	PMC5952272	5/2018	S14-PMC5952272	['approximately 1 in 68 children aged 8\u2009years living in sites participating in the addm network surveillance areas (usa) met the asd case criteria for the 2012 surveillance year.1some HYPOTHESES were SUGGESTED to explain this increase, such as an increased awareness, improved detection, expanding definition, or an actual increase in incidence or a combination of these FACTORS.2ALTHOUGH both Genetic and multiple environmental RISK FACTORS HAVE BEEN studied extensively, many POTENTIALLY modifiable RISK factors including nutritional and Immune function–RELATED RISK FACTORS such as Vitamin D, Folic Acid, and Metabolic syndrome have NOT RECEIVED SUFFICIENT ATTENTION.3SEVERAL RECENT STUDIES have put FORWARD hypotheses to explain the mechanism of ASSOCIATION between both Folic Acid and Vitamin D and autism.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 182), ('INCOMPLETE_EVIDENCE', 198), ('SUPERFICIAL_RELATIONSHIP', 369), ('ANOMALY_CURIOUS_FINDING', 377), ('SUPERFICIAL_RELATIONSHIP', 427), ('INCOMPLETE_EVIDENCE', 440), ('INCOMPLETE_EVIDENCE', 476), ('SUPERFICIAL_RELATIONSHIP', 499), ('SUPERFICIAL_RELATIONSHIP', 554), ('SUPERFICIAL_RELATIONSHIP', 562), ('INCOMPLETE_EVIDENCE', 634), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 668), ('INCOMPLETE_EVIDENCE', 677), ('FUTURE_WORK', 701), ('SUPERFICIAL_RELATIONSHIP', 748)]	15	[('SO_0000704', 'gene', 392, 'genetic'), ('UBERON_0002405', 'immune system', 538, 'immune'), ('CHEBI_27300', 'vitamin D', 583, 'vitamin D'), ('CHEBI_30751', 'formic acid', 594, 'folic acid'), ('GO_0008152', 'metabolic process', 610, 'metabolic'), ('CHEBI_30751', 'formic acid', 773, 'folic acid'), ('CHEBI_27300', 'vitamin D', 788, 'vitamin D')]
S112-PMC5952272	PMC5952272	5/2018	S112-PMC5952272	['while all Nutrients are IMPORTANT for Brain Development, certain Nutrients (eg, protein, Long-Chain polyunsaturated Fatty Acids, iron, copper, zinc, Iodine, Folate, Choline, and Vitamins A, B6, and B12) have particularly large EFFECTS early in Life and exhibit CRITICAL or sensitive periods for Neurodevelopment.8all highly Metabolic, rapidly developing Organs have high iron requirements BECAUSE iron supports fundamental Metabolic Processes.9early-Life id is PARTICULARLY DETRIMENTAL as this is a period of rapid Neurodevelopment.']	[('IMPORTANT_CONSIDERATION', 24), ('SUPERFICIAL_RELATIONSHIP', 227), ('IMPORTANT_CONSIDERATION', 261), ('PROBABLE_UNDERSTANDING', 389), ('ANOMALY_CURIOUS_FINDING', 461), ('IMPORTANT_CONSIDERATION', 474)]	6	[('CHEBI_33284', 'nutrient', 10, 'nutrients'), ('GO_0007420', 'brain development', 38, 'brain development'), ('UBERON_0000955', 'brain', 38, 'brain'), ('CHEBI_33284', 'nutrient', 65, 'nutrients'), ('CHEBI_28911', 'cob(III)alamin', 89, 'long-chain'), ('CHEBI_35366', 'fatty acid', 116, 'fatty acids'), ('CHEBI_24859', 'iodine atom', 149, 'iodine'), ('CHEBI_30863', '5-azaorotic acid', 157, 'folate'), ('CHEBI_15354', 'choline', 165, 'choline'), ('CHEBI_27300', 'vitamin D', 178, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 178, 'vitamins A'), ('PR_000004690', 'B-cell lymphoma/leukemia 11A', 190, 'B6'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 198, 'B12'), ('UBERON_0000104', 'life cycle', 244, 'life'), ('GO_0007399', 'nervous system development', 295, 'neurodevelopment'), ('GO_0008152', 'metabolic process', 324, 'metabolic'), ('UBERON_0000062', 'organ', 354, 'organs'), ('GO_0008152', 'metabolic process', 423, 'metabolic processes'), ('UBERON_0000104', 'life cycle', 450, 'life'), ('GO_0007399', 'nervous system development', 515, 'neurodevelopment')]
S27-PMC5273824	PMC5273824	1/2017	S27-PMC5273824	['RECENTLY, lc-ms/ms became the GOLD STANDARD of measuring Vitamin D level DUE TO its ability to DIFFERENTIATE and ACCURATELY quantify the two subgroups of 25-Oh Vitamin D (25-Oh Vitamin D2 and 25-Oh Vitamin D3); (2) high specificity, which allows DIFFERENTIATION of the target Molecule from other Metabolic intermediates, as well as avoiding INTERFERENCE as SEEN in immunological methods; (3) high sensitivity, which allows detection at ng/ml level.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 30), ('PROBABLE_UNDERSTANDING', 73), ('INCOMPLETE_EVIDENCE', 95), ('SUPERFICIAL_RELATIONSHIP', 113), ('INCOMPLETE_EVIDENCE', 246), ('PROBLEM_COMPLICATION', 341), ('INCOMPLETE_EVIDENCE', 357)]	8	[('CHEBI_28384', 'vitamin K', 57, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 57, 'Vitamin D'), ('CHEBI_86030', 'O-(hydroxyhexadecanoyl)carnitine', 156, '-OH'), ('CHEBI_28384', 'vitamin K', 160, 'Vitamin D'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 171, '25-OH'), ('CHEBI_28934', 'vitamin D2', 177, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 177, 'Vitamin D2'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 192, '25-OH'), ('CHEBI_33237', 'vitamin D4', 198, 'Vitamin D3'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 198, 'Vitamin D3'), ('CHEBI_36357', 'polyatomic entity', 276, 'molecule'), ('GO_0008152', 'metabolic process', 296, 'metabolic')]
